US20080075692A1 - Methods for treating blood disorders - Google Patents

Methods for treating blood disorders Download PDF

Info

Publication number
US20080075692A1
US20080075692A1 US11/746,543 US74654307A US2008075692A1 US 20080075692 A1 US20080075692 A1 US 20080075692A1 US 74654307 A US74654307 A US 74654307A US 2008075692 A1 US2008075692 A1 US 2008075692A1
Authority
US
United States
Prior art keywords
alkenyl
hydrogen
alkoxy
amino
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/746,543
Inventor
Susan Perrine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colorado State University Research Foundation
Viracta Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/746,543 priority Critical patent/US20080075692A1/en
Assigned to HEMAQUEST PHARMACEUTICALS, INC. reassignment HEMAQUEST PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PERRINE, SUSAN P.
Assigned to HEMAQUEST PHARMACEUTICALS, INC. reassignment HEMAQUEST PHARMACEUTICALS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: HEMAGENEX PHARMACEUTICALS, INC.
Publication of US20080075692A1 publication Critical patent/US20080075692A1/en
Priority to US12/212,000 priority patent/US8759378B2/en
Assigned to COLORADO STATE UNIVERSITY RESEARCH FOUNDATION reassignment COLORADO STATE UNIVERSITY RESEARCH FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WILLIAMS, ROBERT M, GRESHOCK, THOMAS J
Priority to US14/310,955 priority patent/US9095565B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles

Definitions

  • the present invention relates to methods and compounds for the treatment of blood disorders.
  • red blood cells The major function of red blood cells is to transport oxygen to tissues of the body, while minor functions include the transportation of nutrients and cytokines and the absorption of cellular metabolites.
  • Anemia defined as a loss of red blood cells or red blood cell capacity resulting in the reduction in the ability of the blood to transport oxygen, may be chronic or acute. Chronic anemia may be caused by extrinsic red blood cell abnormalities, intrinsic abnormalities or impaired production of red blood cells. Extrinsic or extra-corpuscular abnormalities include antibody-mediated disorders such as transfusion reactions and erythroblastosis, mechanical trauma to red cells such as micro-angiopathic hemolytic anemias, thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. In addition, infections by parasites such as Plasmodium, chemical injuries from, for example, lead poisoning, and sequestration in the mononuclear system such as by hyperspienism can result in red blood cell disorders and deficiencies.
  • Impaired red blood cell production can occur by disturbing the proliferation and differentiation of the stem cells or committed cells.
  • Some of the more common diseases of red cell production include aplastic anemia, sickle cell anemia, ⁇ -thalassemia, hypoplastic anemia, pure red cell aplasia and anemia associated with renal failure or endocrine disorders.
  • Disturbances of the proliferation and differentiation of erythroblasts include defects in DNA synthesis such as impaired utilization of vitamin B 12 or folic acid and the megaloblastic anemias, defects in heme or globin synthesis, and anemias of unknown origins such as sideroblastic anemia, anemia associated with chronic infections such as malaria, trypanosomiasis, HIV, hepatitis virus or other viruses, and myelophthisic anemias caused by marrow deficiencies.
  • Symptoms of anemia include feelings of weakness or fatigue, pallor, shortness of breath, an increase in cardiac output, which may lead to palpitations and sweatiness. In severe cases, anemia can lead to death by heart failure. Current treatments for anemia depend on the type of anemia the patient suffers from. Monitoring of the diet to increase iron intake may be prescribed, as well as iron supplementation. In some cases, medication or blood transfusions may be necessary.
  • Sickle cell disease and ⁇ -thalassemia are two of the most common genetic disorders in the word. These disorders are caused by molecular mutations affecting the ⁇ -globin genes for adult hemoglobin A ( ⁇ 2 ⁇ 2), and it has been established that these disorders can be ameliorated by reactivating production of fetal hemoglobin (HbF, ⁇ 2 ⁇ 2) in the patients' blood. Even small increments in fetal hemoglobin decreases morbidity and mortality in sickle cell disease, while higher levels are necessary to completely ameliorate the symptoms. In ⁇ -thalassemia, increases in fetal globin synthesis, which reduces the excess unbalanced ⁇ -globin chains by 10%, is often enough to decrease the anemia to a level which does not require regular blood transfusions.
  • Short chain fatty acids and derivatives of 2-9 carbons induce expression of ⁇ -globin in cultured erythroid cells, animal models and reporter gene assays, which test activity in activating the ⁇ -globin gene promoter.
  • Several short chain fatty acids induce the ⁇ -globin promoter and have biologic and clinical activity.
  • Pharmacological re-introduction of HbF has been achieved in patients with a prototype short-chain fatty acid, arginine butyrate, resulting in sufficient levels of HbF to ameliorate anemia and reduce clinical complications.
  • Patients treated in a Phase II trial with pulsed butyrate have experienced both biochemical and clinical improvement in their diseases, with excellent safety profiles.
  • the prototype short chain fatty acids have limitations as therapeutics.
  • Arginine butyrate and phenylbutyrate require 100 ⁇ M levels in vitro and are rapidly metabolized in vivo, necessitating large quantities (20 g for sodium phenyl butyrate), an intravenous infusion for arginine butyrate and careful adjustment of dosing to prevent secondary suppression of erythopoiesis.
  • the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula I: wherein
  • R 1 is hydroxy or alkoxy
  • X is C(O), C(S), SO, SO 2 or PO 2 ;
  • R 2 and R 3 are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R 4 is alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, halogen or
  • R 5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 6 to form a ring;
  • R 6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 5 or R 7 to form a ring;
  • R 7 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 6 or R 8 to form a ring;
  • R 8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 7 or R 9 to form a ring;
  • R 9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 8 to form a ring;
  • R 4 is R 5 , R 6 , R 7 , R 8 , and R 9 are each not hydrogen; and when R 6 , R 7 , R 8 , and R 9 are each hydrogen, R 5 is not methoxy; and when R 5 , R 7 , R 8 , R 9 are hydrogen, R 6 is not methoxy; and when R 5 , R 8 and R 9 are hydrogen, R 6 and R 7 are not methoxy.
  • the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula II: wherein
  • R 1′ is hydroxy or alkoxy
  • Y is C(O);
  • n is 0 or an integer from 1 to 5;
  • R 10 and R 10′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino, heterocyclic or optionally joined to form a ring;
  • R 11 is CR 11′ R 11′′ R 11′′′ , alkenyl, cycloalkyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, carbonylalkyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxy, halogen or
  • R 11′ and R 11′′ are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxyl, halogen, or R 11′ and R 11′′ are optionally joined to form a ring;
  • R 11′′′ is alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or halogen;
  • R 12 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic or optionally linked to R 13 to form a ring;
  • R 13 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or optionally linked to R 12 or R 14 to form a ring;
  • R 14 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R 13 or R 15 to form a ring;
  • R 15 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R 14 or R 16 to form a ring;
  • R 16 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R 15 to form a ring;
  • R 11 is R 12 , R 13 , R 14 , R 15 , and R 16 are each not hydrogen; and provided when n is 2, R 11 is and R 10 , R 10′ , R 12 , R 15 , and R 16 are hydrogen, then R 14 and R 15 are not methoxy; and provided when n is 1, R 11 is and R 10 , R 10′ , R 13 , R 14 , and R 16 are hydrogen, then R 12 and R 15 are not methoxy.
  • the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula III: wherein
  • R 1′′ is hydroxy or alkoxy
  • Z is C(S), SO, SO 2 or PO 2 ;
  • n is 0 or an integer from 1-5;
  • R 17 and R 17′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R 18 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxyl or halogen;
  • the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula:
  • the present invention pertains, at least in part, to pharmaceutical compositions of an effective amount of a compound of formula I, formula II, formula III, or and a pharmaceutically acceptable carrier.
  • the present invention pertains, at least in part, to compounds of formula I, formula II, and formula (III) and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof.
  • the present invention pertains, at least in part, to methods
  • R 1 is hydroxy or alkoxy
  • X is C(O), C(S), SO, SO 2 or PO 2 ;
  • R 2 and R 3 are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R 4 is alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, halogen or
  • R 5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 6 to form a ring;
  • R 6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 5 or R 7 to form a ring;
  • R 7 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 6 or R 8 to form a ring;
  • R 8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 7 or R 9 to form a ring;
  • R 9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 9 to form a ring;
  • R 4 is R 5 , R 6 , R 7 , R 8 , and R 9 are each not hydrogen; and when R 6 , R 7 , R 8 , and R 9 are each hydrogen, R 5 is not methoxy; and when R 5 , R 7 , R 8 , R 9 are hydrogen, R 6 is not methoxy; and when R 5 , R 8 and R 9 are hydrogen, R 6 and R 7 are not methoxy.
  • R 1 is hydroxy
  • X is C(O)
  • R 4 is
  • R 2 , R 3 , R 5 , R 6 , R 8 and R 9 are each hydrogen and R 7 is alkoxy (e.g., methoxy).
  • R 2 , R 3 , R 5 , R 7 and R 8 are each hydrogen, and R 6 and R 9 are each alkyl (e.g., methyl).
  • R 2 , R 3 , R 5 , R 8 are R 9 are each hydrogen and R 6 and R 7 are each hydroxyl.
  • R 2 , R 3 , R 5 , R 8 are R 9 are each hydrogen and R 6 and R 7 are linked by —O—CH 2 —O— to form a ring.
  • R 2 , R 3 , R 5 , R 6 and R 9 are each hydrogen, R 7 is alkoxy (e.g., methoxy) and R 8 is hydroxyl.
  • R 1 is hydroxy
  • X is C(O)
  • R 4 is heteroaryl, such quinoline or substituted or unsubstituted thiophene (e.g., chlorothiophene).
  • the present invention pertains, at least in part, to methods
  • the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula II: wherein
  • R 1′ is hydroxy or alkoxy
  • Y is C(O);
  • n is 0 or an integer from 1 to 5;
  • R 10 and R 10′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino, heterocyclic or optionally joined to form a ring;
  • R 11 is CR 11′ R 11′′ R 11′′′ , alkenyl, cycloalkyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, carbonylalkyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxy, halogen or
  • R 11′ and R 11′′ are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxyl, halogen or R 11′ and R 11′′ are optionally joined to form a ring;
  • R 11′′′ is alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or halogen;
  • R 12 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic or optionally linked to R 13 to form a ring;
  • R 13 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or optionally linked to R 12 or R 14 to form a ring;
  • R 14 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R 13 or R 15 to form a ring;
  • R 15 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R 14 or R 16 to form a ring;
  • R 16 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R 15 to form a ring;
  • R 11 is R 12 , R 13 , R 14 , R 15 , and R 16 are each not hydrogen; and provided when n is 2, R 11 is and R 10 , R 10′ , R 12 , R 15 , and R 16 are hydrogen, then R 14 and R 15 are not methoxy; and provided when n is 1, R 11 is and R 10 , R 10′ , R 13 , R 14 , and R 16 are hydrogen, then R 12 and R 15 are not methoxy.
  • R 1′ is hydroxyl
  • n is 5
  • R 10 and R 10′ are hydrogen and R 11 is alkylcarbonyl.
  • R 1′ is hydroxyl
  • n is 2
  • R 10 and R 10′ are each hydrogen and R 11 is CR 11′ R 11′′ R 11′′′ .
  • R 11′ and R 11′′ are joined by —(CH 2 ) 5 — to form a cyclohexyl ring and R 11′′′ is a substituted or unsubstituted heterocycle (e.g., chlorothiophene).
  • R 1′ is hydroxyl
  • n is 0 and R 11 is
  • R 13 , R 14 , R 15 , and R 16 are hydrogen and R 12 is arylthioalkyl or alkoxy substituted aryloxy.
  • R 12 , R 14 , R 15 and R 16 are hydrogen and R 13 is a substituted or unsubstituted heterocycle, such as, for example, chromen-2-one, nitro-substituted pyrazole, or chloro-substituted pyrazole.
  • R 12 , R 13 , R 15 and R 16 are hydrogen and R 13 is alkoxy (e.g., ethoxy).
  • R 12 , R 15 and R 16 are hydrogen, and R 13 and R 14 are linked by —N(H)C(O)CH 2 S— to form a ring.
  • R 14 , R 15 and R 16 are each hydrogen, and R 12 and R 13 are linked by —CH ⁇ C(CH 3 )O— to form a ring.
  • R 1′ is hydroxyl
  • n is 0
  • R 11 is a substituted or unsubstituted heterocycle (e.g., substituted aryl-substituted furan) or a substituted or unsubstituted cycloalkyl (e.g., tetrahydrobenzothiadiazole or dihydrobenzothiophenone).
  • R 1′ is hydroxyl
  • n is 1
  • R 10 and R 10′ are hydrogen and R 11 is a substituted or unsubstituted cycloalkyl (e.g., dimethylcyclobutane carboxylic acid).
  • R 1′ is hydroxyl
  • n is 1
  • R 10 and R 10′ are hydrogen and R 11 is
  • R 12 , R 13 and R 16 are hydrogen, and R 14 and R 15 are linked by —O—CH 2 —O— to form a ring.
  • R 1′ is hydroxyl
  • n is 1
  • R 10 and R 10′ are hydrogen and R 11 is a substituted or unsubstituted heterocycle, such as, for example substituted thiazolidinedione, substituted pyridinone or substituted pyrazole.
  • R 1′ is hydroxyl
  • n is 1
  • R 10 and R 10′ are hydrogen and R 11 is a unsubstituted or substituted arylamino (e.g., trifluorothio-substituted arylamino).
  • R 1′ is hydroxyl
  • n is 1
  • R 10 and R 10′ are hydrogen and R 11 is unsubstituted or substituted arylthio (e.g., methoxyphenylthio) or unsubstituted or substituted heterocyclic thio, such as, for example, substituted triazolethio, substituted thiadiazolethio or substituted thiophenethio.
  • arylthio e.g., methoxyphenylthio
  • heterocyclic thio such as, for example, substituted triazolethio, substituted thiadiazolethio or substituted thiophenethio.
  • R 1′ is hydroxyl
  • n is 1
  • R 10 and R 10′ are hydrogen and R 11 is R 11 is CR 11′ R 11′′ R 11′′′ and R 11′ is hydrogen, R 11′′ is amino and R 11′′′ is alkoxy-substituted aryl.
  • R 1′ is hydroxyl, n is 1, R 10 is hydrogen and R 10′ is alkyl.
  • R 10′ is isopropyl and R 11 is substituted or unsubstituted arylthio, such as, for example, alkoxy-substituted phenylthio or alkoxy-substituted pyrimadinylthio.
  • R 10′ is ethyl and R 11 is heteroarylamino (e.g., quinazolinylamino).
  • R 1′ is hydroxyl
  • n is 1
  • R 10 and R 10′ are linked by —(CH 2 ) 5 — to form a cyclohexyl ring and R 11 is heterocyclic substituted carbonylalkyl.
  • the compounds of formula (II) do not include compounds wherein R 1 is hydroxy, R 10 is alkyl, e.g., ethyl, R 10′ is hydrogen, n is 1, and R 11 is arylamino, e.g., quinazolin-4-ylamino.
  • the compounds of formula (II) do not include compounds wherein R 1 is hydroxy, R 10 is hydrogen, R 10′ is alkyl, e.g., ethyl, n is 1, and R 11 is arylamino, e.g., quinazolin-4-ylamino.
  • the compounds of formula (II) do not include compounds wherein R 1 is hydroxy, R 10 and R 10′ are each hydrogen, n is 1, and R 11 is aryl amino (e.g., trifluorothio-substituted arylamino).
  • the compounds of formula (II) do not include 2-(quinazolin-4-ylamino)butyric acid or [4-[(trifluoromethyl)sulfanyl]-anilino]-acetic acid.
  • the present invention pertains, at least in part, to methods
  • the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula III: wherein
  • R 1′′ is hydroxy or alkoxy
  • Z is C(S), SO, SO 2 or PO 2 ;
  • n is 0 or an integer from 1-5;
  • R 17 and R 17′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R 18 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxyl or halogen;
  • R 1′′ is hydroxyl
  • Z is SO 2
  • m is 0, and R 18 is disubstituted aryl substituted by, for example, nitro and fluoro.
  • the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula III, wherein the compound of formula III is:
  • the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula:
  • the invention pertains, at least in part, to a compound of formula I: wherein
  • R 1 is hydroxy or alkoxy
  • X is C(O), C(S), SO, SO 2 or PO 2 ;
  • R 2 and R 3 are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R 4 is alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, halogen or
  • R 5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 6 to form a ring;
  • R 6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 5 or R 7 to form a ring;
  • R 7 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 6 or R 8 to form a ring;
  • R 8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 7 or R 9 to form a ring;
  • R 9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R 8 to form a ring;
  • R 4 is R 5 , R 6 , R 7 , R 8 , and R 9 are each not hydrogen; and when R 6 , R 7 , R 8 , and R 9 are each hydrogen, R 5 is not methoxy; and when R 5 , R 7 , R 8 , R 9 are hydrogen, R 6 is not methoxy; and when R 5 , R 8 and R 9 are hydrogen, R 6 and R 7 are not methoxy;
  • the present invention also pertains, at least in part, to a compound of formula II: wherein
  • R 1′ is hydroxy or alkoxy
  • Y is C(O);
  • n is 0 or an integer from 1 to 5;
  • R 10 and R 10′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino, heterocyclic or optionally joined to form a ring;
  • R 11 is CR 11′ R 11′′ R 11′′′ , alkenyl, cycloalkyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, carbonylalkyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxy, halogen or
  • R 11′ and R 11′′ are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxyl, halogen or R 11′ and R 11′′ are optionally joined to form a ring;
  • R 11′′′ is alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or halogen;
  • R 12 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic or optionally linked to R 13 to form a ring;
  • R 13 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or optionally linked to R 12 or R 14 to form a ring;
  • R 14 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R 13 or R 15 to form a ring;
  • R 15 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R 14 or R 16 to form a ring;
  • R 16 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R 15 to form a ring;
  • R 11 is R 12 , R 13 , R 14 , R 15 , and R 16 are each not hydrogen; and provided when n is 2, R 11 is and R 10 , R 10′ , R 12 , R 15 , and R 16 are hydrogen, then R 14 and R 15 are not methoxy; and provided when n is 1, R 11 is and R 10 , R 10′ , R 13 , R 14 , and R 16 are hydrogen, then R 12 and R 15 are not methoxy;
  • the present invention pertains, at least in part, to a compound of formula III: wherein
  • R 1′′ is hydroxy or alkoxy
  • Z is C(S), SO, SO 2 or PO 2 ;
  • n is 0 or an integer from 1-5;
  • R 17 and R 17′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R 18 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxyl or halogen;
  • the compounds of the invention do not include the compounds described in S. Casteneda et al., Blood Cells, Molecules, and Diseases, 35 (2005) 217-226.
  • alkyl includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
  • straight-chain alkyl groups e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl,
  • alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
  • a straight chain or branched chain alkyl has 6 or fewer carbon atoms in its backbone (e.g., C 1 -C 6 for straight chain, C 3 -C 6 for branched chain), and more preferably 4 or fewer.
  • preferred cycloalkyls have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
  • C 1 -C 6 includes alkyl groups containing 1 to 6 carbon atoms.
  • alkyl includes both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sul
  • Cycloalkyls can be further substituted, e.g., with the substituents described above.
  • An “alkylaryl” or an “arylalkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)).
  • the term “alkyl” also includes the side chains of natural and unnatural amino acids.
  • aryl includes groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiaozole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
  • aryl includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxophenyl, quinoline, isoquinoline, naphthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine.
  • aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles”, “heterocycles,” “heteroaryls” or “heteroaromatics”.
  • the aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and
  • alkenyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
  • alkenyl includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups.
  • alkenyl includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonen
  • alkenyl further includes alkenyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
  • a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
  • cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
  • C 2 -C 6 includes alkenyl groups containing 2 to 6 carbon atoms.
  • alkenyl includes both “unsubstituted alkenyls” and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,
  • alkynyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
  • alkynyl includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups.
  • alkynyl further includes alkynyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
  • a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
  • the term C 2 -C 6 includes alkynyl groups containing 2 to 6 carbon atoms.
  • alkynyl includes both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,
  • lower alkyl as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure. “Lower alkenyl” and “lower alkynyl” have chain lengths of, for example, 2-5 carbon atoms.
  • acyl includes compounds and moieties which contain the acyl radical (CH 3 CO—) or a carbonyl group. It includes substituted acyl moieties.
  • substituted acyl includes acyl groups where one or more of the hydrogen atoms are replaced by for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including
  • acylamino includes moieties wherein an acyl moiety is bonded to an amino group.
  • the term includes alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.
  • aroyl includes compounds and moieties with an aryl or heteroaromatic moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl carboxy, etc.
  • alkoxyalkyl examples include alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms.
  • alkoxy includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom.
  • alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups.
  • substituted alkoxy groups include halogenated alkoxy groups.
  • the alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate
  • amine or “amino” includes compounds where a nitrogen atom is covalently bonded to at least one carbon or heteroatom.
  • alkyl amino includes groups and compounds wherein the nitrogen is bound to at least one additional alkyl group.
  • dialkyl amino includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups.
  • arylamino and “diarylamino” include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively.
  • alkylarylamino “alkylaminoaryl” or “arylaminoalkyl” refers to an amino group which is bound to at least one alkyl group and at least one aryl group.
  • alkaminoalkyl or “alkyl aminoalkyl” refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
  • amide or “aminocarbonyl” includes compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group.
  • the term includes “alkaminocarbonyl” or “alkylaminocarbonyl” groups which include alkyl, alkenyl, aryl or alkynyl groups bound to an amino group bound to a carbonyl group. It includes arylaminocarbonyl groups which include aryl or heteroaryl moieties bound to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group.
  • alkylaminocarbonyl alkenylaminocarbonyl
  • alkynylaminocarbonyl arylaminocarbonyl
  • alkylcarbonylamino alkenylcarbonylamino
  • alkynylcarbonylamino alkynylcarbonylamino
  • arylcarbonylamino alkylcarbonylamino
  • Amides also include urea groups (aminocarbonylamino) and carbamates (oxycarbonylamino).
  • carbonyl or “carboxy” includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom.
  • the carbonyl can be further substituted with any moiety which allows the compounds of the invention to perform its intended function.
  • carbonyl moieties may be substituted with alkyls, alkenyls, alkynyls, aryls, alkoxy, aminos, etc.
  • moieties which contain a carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
  • thiocarbonyl or “thiocarboxy” includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom.
  • ether includes compounds or moieties which contain an oxygen bonded to two different carbon atoms or heteroatoms.
  • alkoxyalkyl which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group.
  • esters includes compounds and moieties which contain a carbon or a heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group.
  • ester includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc.
  • alkyl, alkenyl, or alkynyl groups are as defined above.
  • thioether includes compounds and moieties which contain a sulfur atom bonded to two different carbon or hetero atoms.
  • Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls, and alkthioalkynyls.
  • alkthioalkyls include compounds with an alkyl, alkenyl, or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group.
  • alkthioalkenyls and alkthioalkynyls refer to compounds or moieties wherein an alkyl, alkenyl, or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkynyl group.
  • hydroxy or “hydroxyl” includes groups with an —OH or —O ⁇ .
  • halogen includes fluorine, bromine, chlorine, iodine, etc.
  • perhalogenated generally refers to a moiety wherein all hydrogens are replaced by halogen atoms.
  • polycyclyl or “polycyclic radical” refer to two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings.
  • Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, alkylaminoacarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkyl carbonyl, alkenylcarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and
  • heteroatom includes atoms of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.
  • ring means cycloalkyl or aryl as these terms are used and defined herein.
  • prodrug moiety includes moieties which can be metabolized in vivo and moieties which may advantageously remain esterified or otherwise protected in vivo.
  • the prodrugs moieties are metabolized in vivo by esterases or by other mechanisms to hydroxyl groups or other advantageous groups.
  • Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19).
  • the prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent.
  • Hydroxyl groups can be converted into esters via treatment with a carboxylic acid.
  • prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides,
  • the structure of some of the compounds of this invention includes asymmetric carbon atoms, and thus may exist as racemic mixtures or as isolated isomeric forms. It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof.
  • the present invention pertains, at least in part, to methods for treating a blood disorder in a subject by administering to the subject an effective amount of a compound of the invention (e.g., a compound of Formula I, II, III or otherwise described herein, including isolated enantiomers or diastereomers).
  • a compound of the invention e.g., a compound of Formula I, II, III or otherwise described herein, including isolated enantiomers or diastereomers.
  • treating includes curing as well as ameliorating at least one symptom of the state, disease or disorder, e.g., the blood disorder. Therefore, prevention of blood disorders or at least one symptom thereof is also contemplated herein.
  • blood disorder includes disorders which can be treated, prevented, or otherwise ameliorated by the administration of a compound of the invention, e.g., a compound of formula I, II, III or otherwise described herein).
  • a blood disorder is any disorder of the blood and blood-forming organs.
  • the term blood disorder includes nutritional anemias (e.g., iron deficiency anemia, sideropenic dysphasia, Plummer-Vinson syndrome, vitamin B 12 deficiency anemia, vitamin B 12 deficiency anemia due to intrinsic factor, pernicious anemia, folate deficiency anemia, and other nutritional anemias), myelodysplastic syndrome, bone marrow failure or anemia resulting from chemotherapy, radiation or other agents or therapies, hemolytic anemias (e.g., anemia due to enzyme disorders, anemia due to phosphate dehydrogenase (G6PD) deficiency, favism, anemia due to disorders of glutathione metabolism, anemia due to disorders of glycolytic enzymes, anemias due to disorders of nucleotide metabolism and anemias due to unspecified enzyme disorder), thalassemia ⁇ -thalassemia, ⁇ -thalassemia, ⁇ -thalassemia, thalassemia trait, hereditary persistence of fetal
  • the compounds of formula I, II, III or otherwise described herein stimulate fetal hemoglobin production, hematopoiesis, erythropoiesis, myelopoiesis and/or neutrophil production upon administration to a subject for the treatment of a blood disorder.
  • the compounds of formula I, II, III or otherwise described are administered to the subject for treatment of a blood disorder in combination with one or more cytokines.
  • the cytokine is selected from the group consisting of IL-3, GM-CSF, G-CSF, stem cell factor (SCF) and IL-6.
  • one or more compounds of the invention may be administered alone to a subject, or more typically a compound of the invention will be administered as part of a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral or other desired administration and which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof.
  • conventional excipient i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral or other desired administration and which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof.
  • the invention pertains, at least in part to a pharmaceutical composition of an effective amount of a compound of formula I, formula II, formula III, or and racemates, isolated enantiomers or diastereomers thereof, and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier includes substances capable of being coadministered with the compound(s) of the invention and which allow both to perform their intended function, e.g., treat or prevent a blood disorder.
  • Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc.
  • the pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds of the invention.
  • auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds of the invention.
  • the compounds of the invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of the compounds of the invention that are basic in nature are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulf
  • salts must be pharmaceutically acceptable for administration to a subject, e.g., a mammal
  • the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
  • the preparation of other compounds of the invention not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.
  • the compounds of the invention that are acidic in nature are capable of forming a wide variety of base salts.
  • the chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of the invention that are acidic in nature are those that form non-toxic base salts with such compounds.
  • Such non-toxic base salts include, but are not limited to those derived from such pharmaceutically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
  • the pharmaceutically acceptable base addition salts of compounds of the invention that are acidic in nature may be formed with pharmaceutically acceptable cations by conventional methods.
  • these salts may be readily prepared by treating the compound of the invention with an aqueous solution of the desired pharmaceutically acceptable cation and evaporating the resulting solution to dryness, preferably under reduced pressure.
  • a lower alkyl alcohol solution of the compound of the invention may be mixed with an alkoxide of the desired metal and the solution subsequently evaporated to dryness.
  • the compounds of the invention and pharmaceutically acceptable salts thereof can be administered via either the oral, parenteral or topical routes.
  • these compounds are most desirably administered in effective dosages, depending upon the weight and condition of the subject being treated and the particular route of administration chosen. Variations may occur depending upon the species of the subject being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out.
  • compositions of the invention may be administered alone or in combination with other known compositions for treating blood disorders in a subject, e.g., a mammal.
  • Preferred mammals include cats, dogs, pigs, rats, mice, monkeys, chimpanzees, baboons and humans.
  • the subject is suffering from a blood disorder.
  • the subject is at risk of suffering from a blood disorder.
  • composition of the invention in combination with a known composition is intended to include simultaneous administration of the composition of the invention and the known composition, administration of the composition of the invention first, followed by the known composition and administration of the known composition first, followed by the composition of the invention.
  • Any of the therapeutically composition known in the art for treating blood disorders can be used in the methods of the invention.
  • the compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the routes previously mentioned, and the administration may be carried out in single or multiple doses.
  • the novel therapeutic agents of this invention can be administered advantageously in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like.
  • Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc.
  • oral pharmaceutical compositions can be suitably sweetened and/or flavored.
  • the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
  • tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
  • compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed.
  • the aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic.
  • These aqueous solutions are suitable for intravenous injection purposes.
  • the oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
  • suitable preparations include solutions, preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories.
  • Therapeutic compounds may be formulated in sterile form in multiple or single dose formats such as being dispersed in a fluid carrier such as sterile physiological saline or 5% saline dextrose solutions commonly used with injectables.
  • topical administration examples include transdermal, buccal or sublingual application.
  • therapeutic compounds can be suitably admixed in a pharmacologically inert topical carrier such as a gel, an ointment, a lotion or a cream.
  • topical carriers include water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils.
  • topical carriers are liquid petrolatum, isopropylpalmitate, polyethylene glycol, ethanol 95%, polyoxyethylene monolauriate 5% in water, sodium lauryl sulfate 5% in water, and the like.
  • materials such as anti-oxidants, humectants, viscosity stabilizers and the like also may be added if desired.
  • tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like are particularly suitable, the carrier preferably being lactose and/or corn starch and/or potato starch.
  • a syrup, elixir or the like can be used wherein a sweetened vehicle is employed.
  • Sustained release compositions can be formulated including those wherein the active component is derivatized with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.
  • compounds of the invention for treatment can be administered to a subject in dosages used in prior therapies.
  • a suitable effective dose of one or more compounds of the invention will be in the range of from 0.01 to 100 milligrams per kilogram of body weight of recipient per day, preferably in the range of from 0.1 to 50 milligrams per kilogram body weight of recipient per day, more preferably in the range of 1 to 20 milligrams per kilogram body weight of recipient per day.
  • the desired dose is suitably administered once daily, or several sub-doses, e.g. 2 to 5 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule.
  • the invention also pertains to the use of a compound of formula I, II, III or a compound otherwise described herein for the preparation of a medicament.
  • the medicament may include a pharmaceutically acceptable carrier and the compound is an effective amount, e.g., an effective amount to treat a blood disorder.
  • the pharmacophore was constructed with the TFIT module of the FLO molecular modeling software. It was assumed that the carboxylic acids would bind to the receptor in an analogous fashion, and therefore, the superposition of the carboxylic oxygens was biased by imposing a 5 kJ superimposition energy constraint. Five hundred iterations of TFIT were used in the calculations.
  • TFIT produced an ensemble of low energy superimposition. The superimposition with the tightest overlay was taken to be the initial pharmacophore template. This pharmacophore was tested to see if it could distinguish between active and inactive compounds. TFIT was first used to determine the best match between the pharmacophore and four compounds which had been identified as inactive in the ⁇ / ⁇ -globin promoter driven reporter gene assay in previous studies.
  • the TFIT was next used to determine how well five additional compounds, which were active in the ⁇ / ⁇ -globin promoter driven reporter gene assay would match the template.
  • the template was used to design and select new compounds for testing. Compounds were selected from available compound data bases and evaluated by fitting them onto the template with TFIT.
  • a “pseudo” receptor was constructed around the pharmacophore by refining the original pharmacophore template.
  • a new template was constructed by adding two of the most active new compounds. The compounds were selected primarily for the additional structural information that they contained.
  • the “pseudo” binding site was construction using FLO.
  • This “pseudo” binding site was composed of functional groups selected to form hydrogen bonds with the ligands, and functional groups that would mimic the hydrophobic surface of the binding site.
  • a guanidinium group was selected form hydrogen bonds with the acidic groups of the ligands.
  • a pyrrole group was used to mimic the binding site hydrogen bond donors. These groups were positioned around the template molecules and anchored to the chemically complimentary ligand atoms with a 10 kJ constraint.
  • the “pseudo” program of FLO automatically filled the remaining volume with propane to mimic the binding site's hydrophobic surface. This structure was next subject to several rounds of dynamics.
  • the shell of propanes, the pyrrole group and the guanidinium groups represented the receptor binding site.
  • the atoms of the binding site were allowed to move with a molecular mechanics force field and an additional flat well constraint [radius 0.5 ⁇ , quadratic penalty 20 kJ/ ⁇ 2 ] was imposed.
  • FLO+ computed a predicted binding free energy using an empirical scoring function consisting of contact energy, hydrogen bonding energy, polar desolvation, bumping, internal energy and entropy.
  • the predicted free energy (reported as pI or the ⁇ logK i ), fell between 6.6 and 6.9, with hydrogen bonding energies between 7.4 and 8.9 kJ/mol.
  • the pI values for the four inactive compounds ranged from 5.6 to 6.2 with hydrogen bonding energies between 5.6 and 7.0 kJ/mol. A combination of the pI and the hydrogen bonding energy was used to distinguish between active and inactive compounds.
  • Table 2 shows the results of the ⁇ / ⁇ -globin promoter driven reporter gene assay for the twenty-six compounds. ‘*’ indicates a 80-100% increase; ‘**’ indicates a 100%- #200% increase; and ‘***’ indicates an over 200% increase of ⁇ globin promoter induction over untreated controls.
  • test compounds predicted to be active by reporter gene assays and molecular modeling produce a significant increase in fetal (gamma) globin mRNA in cells cultured in vitro. Furthermore, the concentrations required were significantly lower (5-40 micromolar) than concentrations required for prior generation inducers (100-200 micromolar), making these compounds more suitable for therapeutic and pharmacologic compositions
  • ⁇ -globin mRNA was analyzed in control and treated erythroid colonies cultured from cord blood, by RT-PCR.
  • the relative in vitro F-cell production was as follows: W>Y>R>M>P.
  • the relative potency for F-cell production was as follows: R>M>Y>P>W.
  • test compounds predicted to be active by reporter gene assays and molecular modeling produce a significant increase in numbers of erythroid and myeloid colonies or proportion of cells expressing fetal globin in in vitro cultured cells from a variety of sources under a variety of culture conditions. Similar to other in vitro tests described herein, the concentrations required for these biological effects were significantly lower (5-40 micromolar) than concentrations required for prior generation inducers (100-200 micromolar), making these compounds more suitable for therapeutic and pharmacologic compositions.
  • Compounds predicted in the molecular model to be ⁇ -globin inducers were evaluated in a series of assays for activity in 1) stimulating activity from the fetal globin gene promoter, (the action which can ameliorate sickle cell disease and beta thalassemia), and 2) for any effects on stimulating erythroid or myeloid cell growth and proliferation, the action which can treat blood cell deficiencies.
  • BFU-E Erythroid burst-forming units
  • CFU-GM colony-forming units granulocyte-macrophage
  • BFU-E cell proliferation was evaluated by enumeration in colonies developing in the presence of reduced amounts of erythropoietin (0.5 U/ml) rather than 3 U (or 3000 mU)/ml, which is standard for these experimental systems), from cord blood or the peripheral blood of several types of humans.
  • Experiment 2 Erythroid colonies were cultured from patients with beta thalassemia, either without any test compounds (Control), only an optimal panel of hematopoietic growth factors, or with one of the test compounds M, P, T, 2-methyl-1-benzofuran-4-carboxylic acid, V, W, X, Y, AK, AC, or AI. All of the listed test compounds increased the number of colonies as compared to the matched control cultures that were grown with an optimal panel of growth factors alone. Colony numbers were increased above the control cultures (% BFU-E/Control) by anywhere from 25% to 230%. Each of the listed test compounds was tested in at least 5 different patients' blood and the differences were statistically signficant.
  • BFU-E cultured from cord blood was tested with or without compound M, P, R, T, W, Y, Z, AI, F, or 3-(5-chlorothien-3-yl)acrylic acid.
  • the test compounds all induced increased numbers of colonies as compared to the controls.
  • the test compounds resulted in 50-250% more colonies than in control cultures from the same source.
  • Experiment 3 Representative novel compounds M, W, X, Y, and AI also stimulated production of myeloid colonies compared to control, untreated myeloid colonies from the same individual. Control colonies were established in cultures with no added growth factors to support myelopoiesis, in Iscove's Modified Dulbecco's Media (IMDM) methylcellulose media with charcoal-absorbed fetal bovine serum, beta mercaptoethanol, BSA. A 30-75% increase in de novo myeloid colonies was observed in cord blood cultured with the novel compounds at the same concentrations as required for increases in erythroid colonies.
  • IMDM Iscove's Modified Dulbecco's Media
  • Erythroid cells were generated by culturing purified CD34+ cells in Flt-3 ligand, stem cell factor (SCF) and IL-3 for seven days followed by growth in EPO for 14 days.
  • SCF stem cell factor
  • IL-3 stem cell factor
  • cells were cultured as above in a T75 flask then split into multiple flasks on day 8 and treatment with the test compounds was begun.
  • Compound P or other test compounds were diluted from stock solutions with the microliter volumes of stock added to each culture flask for final working concentrations. Cells were enumerated every two days by hemacytometer count.
  • RNA was harvested from 10 6 cells every two days using RNeasy Plus Mini Kit (Qiagen) and qRT-PCR performed using IQ SybrGreen Supermix on an Opticon Monitor instrument (MJ Research).
  • QPCR primers were designed using known sequences for ⁇ -globin, ⁇ -globin, ⁇ -globin, ⁇ -actin and B3PD. Primers were designed to span at least one exon.
  • Hemoglobin F protein levels increased in a compound P dose-dependent manner with a 19-fold increase in expression of fetal globin produced at 100 micromolar compound P as compared to untreated control cultures from the same subject with just one cycle of erythroid differentiation.
  • test compounds M, P, 2-methyl-1-benzofuran-4-carboxylic acid, V, W, Y (racemic mixture) or AI resulted in an increase in numbers of erythroid colonies of at least 25% above control conditions.
  • Compounds marked with a * are significantly different.
  • 2-methyl-1-benzofuran-4-carboxylic acid and compound V require additional samples for statistical evaluation, but had positive effects in 3/3 different patients' cultures.
  • experiments described in this example show that representative test compounds produce a significant increase in numbers of erythroid and myeloid colonies or proportion of cells expressing fetal globin in in vitro cultured cells derived from a variety of sources under culture conditions relevant to blood conditions including anemia, sickle cell anemia and beta thalassamia.
  • Juvenile baboons were catheterized with venous and arterial catheters, and were phlebotomized a set amount of blood daily to maintain anemia with a hemoglobin level of 7.0-7.5 g/dl, from a baseline normal hemoglobin level of (12-13 g/dl). Normal saline was infused to replace the amount of blood withdrawn. This degree of phlebotomy exchanges the blood volume every 10-20 days.
  • test compound was administered once/day, either intravenously or orally, and blood was withdrawn through the arterial catheter for analysis of globin mRNA or for analysis of the test compound in the plasma by HPLC-MS.
  • Pharmacokinetic profiles were established from the plasma levels and oral bioavailability (comparing area under the curve between IV and oral plasma levels) was determined for the test compounds.
  • compounds AK, Y and M were evaluated in a baboon and demonstrated significant increases in fetal globin expression at tolerable low doses. As shown in the previous Examples, these 3 compounds all stimulated erythroid cell proliferation in vitro and have favorable pharmacokinetic profiles after oral administration. The compounds were administered to an anemic baboon and studied for pharmacodynamic effects on induction of fetal globin, which is known to ameliorate the pathology of sickle cell anemia and beta thalassemia.
  • baseline fetal globin mRNA was 26% of non-alpha globin.
  • fetal globin mRNA increased to 48% of non-alpha globin, an 85% increase over the baseline level.
  • Treatment with compound AK at 50 mg/kg induced a 51% fetal globin mRNA increase, a 96% increase over the baseline level.
  • Compound M treatment at 40 mg/kg induced a 67% fetal globin mRNA increase, a 257% increase over the baseline level.
  • the human equivalent dose is 20% of these doses, or 1 mg/kg, 10 mg/kg, or 8 mg/kg respectively.
  • compound P was evaluated in a phlebotomized, anemic baboon showing no baseline expression of fetal globin and 100% of globin expression as beta globin. Treatment with compound P resulted in an induction of 7% fetal globin and a concomitant reduction in beta globin expression.
  • This example demonstrates that compound W increases expression of human fetal globin mRNA expression and hematocrit in a transgenic mouse model.
  • Compound W was administered to mice transgenic for the micro-LCR-201 gamma-globin gene promoter, by IP injection once/day for 5 days/week for 2 weeks, and gamma-globin mRNA was assayed by qPCR. Hematocrit was analyzed once per week. A significant difference in expression of human fetal globin mRNA and in hematocrit between Control and compound W-treated mice was found in initial experiments as summarized in Table 4 below.
  • Cesium thiobenzoate To a solution of thiobenzoic acid (50.0 g, 361.8 mmol) in methanol (362 mL) was added Cs 2 CO 3 (130 g, 398 mmol) in portions over 5 min. The resulting mixture was stirred 10 min until all solids were dissolved. The resulting solution was concentrated on the rotovap. The solid residue was diluted with 500 mL of acetone and the white solid (CsHCO 3 ) was filtered off. This process was repeated two times to ensure all CsHCO 3 was removed. The acetone was then concentrated to afford cesium thiobenzoate (Strijtveen, B.; Kellogg, R. M. J. Org. Chem.
  • (R)-2-Mercapto-3-methylbutanoic acid To a solution of (R)-2-benzoylthio-3-methylbutanoic acid (4.05 g, 17.0 mmol) in CH 2 Cl 2 (68 mL) was added 3 M aqueous NH 4 OH (68 mL). The mixture was stirred at rt for 3 h. The resulting solution was diluted with 2 M aqueous KOH (68 mL) and washed with CH 2 Cl 2 (6 ⁇ 70 mL) to remove the benzamide. The aqueous layer was then acidified to pH 2 with concentrated aqueous HCl and extracted with CH 2 Cl 2 (4 ⁇ 70 mL).
  • (S)-2-Mercapto-3-methylbutanoic acid To a solution of (S)-2-benzoylthio-3-methylbutanoic acid (3.89 g, 16.3 mmol) in CH 2 Cl 2 (65 mL) was added 3 M aqueous NH 4 OH (65 mL). The mixture was stirred at rt for 3 h. The resulting solution was diluted with 2 M aqueous KOH (65 mL) and washed with CH 2 Cl 2 (6 ⁇ 65 mL) to remove the benzamide. The aqueous layer was then acidified to pH 2 with concentrated aqueous HCl and extracted with CH 2 Cl 2 (4 ⁇ 65 mL).
  • Compound Y exists naturally in a racemic mixture, and has the highly favorable PK properties described above.
  • the experiments described herein demonstrate that the S enantiomer of compound Y stimulates erythroid cell proliferation significantly, while the R enantiomer does not stimulate cell proliferation.
  • the R enantiomer of compound Y has activity in stimulating fetal globin expression (see Table 3).
  • the proliferative activity of compound Y-S enantiomer was tested in vitro in erythroid colonies cultured from peripheral blood of 3 sources of individuals: sickle cell anemia patients who were taking Hydroxyurea and have suppression of their endogenous erythropoiesis, a normal adult subject, and two cord blood samples.
  • the cultures established in high EPO produced 25-45% (mean 35%) more colonies than the cultures established with the racemic mix in low EPO or the R enantiomer in low EPO.
  • Addition of the S— enantiomer of compound Y at the same concentration resulted in a mean of 45% more erythroid colonies than in the racemic mixture (range 38-50%).
  • the S enantiomer demonstrates the activity of stimulating proliferation of erythroid colonies in vitro.
  • the erythroid kruppel-like factor, EKLF is an essential transcription factor for mammalian beta-like globin gene switch, and it specifically activates transcription of the adult beta-globin gene through binding of its zinc fingers to the promoter. It has been shown that transcription factor EKLF is required for activation of the gamma globin gene by the compounds described herein. EKLF was previously considered to activate primarily the beta (adult) globin gene. Transcription factor EKLF is actively recruited to the gamma-globin gene promoter by the compounds described herein.
  • the human SWI/WNF complex is a ubiquitous multimeric complex that regulates gene expression by remodeling nucleosomal structure in an ATP-dependent manner.
  • the SWI/SNF complex contains one of two core ATPases, BRG1 or BRM. These complexes can interact with sequence specific transcription factors to either promote or repress target gene activation, dependent on promoter context and complex content.
  • the SWI/SNF complex chromatin-modifying core ATPase Brg1 is required for gamma globin induction by the compounds described herein.
  • Brg1 the co-activator SWI/SNF complex chromatin-modifying ATPase, is actively recruited to the gamma-globin promoter by the compounds described herein, and this recruitment is dependent upon the presence of EKLF.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Methods of treating blood disorders are described.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 60/799,054 filed May 9, 2006, which provisional application is incorporated herein by reference in its entirety.
    • BACKGROUND
  • 1. Field of the Invention
  • The present invention relates to methods and compounds for the treatment of blood disorders.
  • 2. Description of the Related Art
  • The major function of red blood cells is to transport oxygen to tissues of the body, while minor functions include the transportation of nutrients and cytokines and the absorption of cellular metabolites. Anemia, defined as a loss of red blood cells or red blood cell capacity resulting in the reduction in the ability of the blood to transport oxygen, may be chronic or acute. Chronic anemia may be caused by extrinsic red blood cell abnormalities, intrinsic abnormalities or impaired production of red blood cells. Extrinsic or extra-corpuscular abnormalities include antibody-mediated disorders such as transfusion reactions and erythroblastosis, mechanical trauma to red cells such as micro-angiopathic hemolytic anemias, thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. In addition, infections by parasites such as Plasmodium, chemical injuries from, for example, lead poisoning, and sequestration in the mononuclear system such as by hyperspienism can result in red blood cell disorders and deficiencies.
  • Impaired red blood cell production can occur by disturbing the proliferation and differentiation of the stem cells or committed cells. Some of the more common diseases of red cell production include aplastic anemia, sickle cell anemia, β-thalassemia, hypoplastic anemia, pure red cell aplasia and anemia associated with renal failure or endocrine disorders. Disturbances of the proliferation and differentiation of erythroblasts include defects in DNA synthesis such as impaired utilization of vitamin B12 or folic acid and the megaloblastic anemias, defects in heme or globin synthesis, and anemias of unknown origins such as sideroblastic anemia, anemia associated with chronic infections such as malaria, trypanosomiasis, HIV, hepatitis virus or other viruses, and myelophthisic anemias caused by marrow deficiencies.
  • Symptoms of anemia include feelings of weakness or fatigue, pallor, shortness of breath, an increase in cardiac output, which may lead to palpitations and sweatiness. In severe cases, anemia can lead to death by heart failure. Current treatments for anemia depend on the type of anemia the patient suffers from. Monitoring of the diet to increase iron intake may be prescribed, as well as iron supplementation. In some cases, medication or blood transfusions may be necessary.
  • Sickle cell disease and β-thalassemia are two of the most common genetic disorders in the word. These disorders are caused by molecular mutations affecting the β-globin genes for adult hemoglobin A (α2β2), and it has been established that these disorders can be ameliorated by reactivating production of fetal hemoglobin (HbF, α2γ2) in the patients' blood. Even small increments in fetal hemoglobin decreases morbidity and mortality in sickle cell disease, while higher levels are necessary to completely ameliorate the symptoms. In β-thalassemia, increases in fetal globin synthesis, which reduces the excess unbalanced α-globin chains by 10%, is often enough to decrease the anemia to a level which does not require regular blood transfusions.
  • Short chain fatty acids and derivatives of 2-9 carbons induce expression of γ-globin in cultured erythroid cells, animal models and reporter gene assays, which test activity in activating the γ-globin gene promoter. Several short chain fatty acids induce the γ-globin promoter and have biologic and clinical activity. Pharmacological re-introduction of HbF has been achieved in patients with a prototype short-chain fatty acid, arginine butyrate, resulting in sufficient levels of HbF to ameliorate anemia and reduce clinical complications. Patients treated in a Phase II trial with pulsed butyrate have experienced both biochemical and clinical improvement in their diseases, with excellent safety profiles. However, the prototype short chain fatty acids have limitations as therapeutics. Arginine butyrate and phenylbutyrate require 100 μM levels in vitro and are rapidly metabolized in vivo, necessitating large quantities (20 g for sodium phenyl butyrate), an intravenous infusion for arginine butyrate and careful adjustment of dosing to prevent secondary suppression of erythopoiesis.
  • While advances have been made in this field, there remains a need for new and/or improved methods for treating and preventing blood disorders generally as well as for compounds and pharmaceutical compositions for the same.
    • BRIEF SUMMARY
  • The present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula I:
    Figure US20080075692A1-20080327-C00001
    wherein
  • R1 is hydroxy or alkoxy;
  • X is C(O), C(S), SO, SO2 or PO2;
  • R2 and R3 are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R4 is alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, halogen or
    Figure US20080075692A1-20080327-C00002
  • R5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R6 to form a ring;
  • R6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R5 or R7 to form a ring;
  • R7 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R6 or R8 to form a ring;
  • R8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R7 or R9 to form a ring;
  • R9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R8 to form a ring;
  • and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
  • provided that when R4 is
    Figure US20080075692A1-20080327-C00003
    R5, R6, R7, R8, and R9 are each not hydrogen; and when R6, R7, R8, and R9 are each hydrogen, R5 is not methoxy; and when R5, R7, R8, R9 are hydrogen, R6 is not methoxy; and when R5, R8 and R9 are hydrogen, R6 and R7 are not methoxy.
  • In another embodiment, the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula II:
    Figure US20080075692A1-20080327-C00004
    wherein
  • R1′ is hydroxy or alkoxy;
  • Y is C(O);
  • n is 0 or an integer from 1 to 5;
  • R10 and R10′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino, heterocyclic or optionally joined to form a ring;
  • R11 is CR11′R11″R11′″, alkenyl, cycloalkyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, carbonylalkyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxy, halogen or
    Figure US20080075692A1-20080327-C00005
  • R11′ and R11″ are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxyl, halogen, or R11′ and R11″ are optionally joined to form a ring;
  • R11′″ is alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or halogen;
  • R12 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic or optionally linked to R13 to form a ring;
  • R13 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or optionally linked to R12 or R14 to form a ring;
  • R14 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R13 or R15 to form a ring;
  • R15 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R14 or R16 to form a ring;
  • R16 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R15 to form a ring;
  • and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
  • provided that when R11 is
    Figure US20080075692A1-20080327-C00006
    R12, R13, R14, R15, and R16 are each not hydrogen; and provided when n is 2, R11 is
    Figure US20080075692A1-20080327-C00007
    and R10, R10′, R12, R15, and R16 are hydrogen, then R14 and R15 are not methoxy; and
    provided when n is 1, R11 is
    Figure US20080075692A1-20080327-C00008
    and R10, R10′, R13, R14, and R16 are hydrogen, then R12 and R15 are not methoxy.
  • In yet another embodiment, the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula III:
    Figure US20080075692A1-20080327-C00009
    wherein
  • R1″ is hydroxy or alkoxy;
  • Z is C(S), SO, SO2 or PO2;
  • m is 0 or an integer from 1-5;
  • R17 and R17′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R18 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxyl or halogen;
  • and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof.
  • In another embodiment, the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula:
    Figure US20080075692A1-20080327-C00010
    In one embodiment, the present invention pertains, at least in part, to pharmaceutical compositions of an effective amount of a compound of formula I, formula II, formula III, or
    Figure US20080075692A1-20080327-C00011
    and a pharmaceutically acceptable carrier.
  • In another embodiment, the present invention pertains, at least in part, to compounds of formula I, formula II, and formula (III) and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof.
    • DETAILED DESCRIPTION
  • In one embodiment, the present invention pertains, at least in part, to methods
  • for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula I:
    Figure US20080075692A1-20080327-C00012
    wherein
  • R1 is hydroxy or alkoxy;
  • X is C(O), C(S), SO, SO2 or PO2;
  • R2 and R3 are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R4 is alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, halogen or
    Figure US20080075692A1-20080327-C00013
  • R5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R6 to form a ring;
  • R6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R5 or R7 to form a ring;
  • R7 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R6 or R8 to form a ring;
  • R8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R7 or R9 to form a ring;
  • R9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R9 to form a ring;
  • and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
  • provided that when R4 is
    Figure US20080075692A1-20080327-C00014
    R5, R6, R7, R8, and R9 are each not hydrogen; and when R6, R7, R8, and R9 are each hydrogen, R5 is not methoxy; and when R5, R7, R8, R9 are hydrogen, R6 is not methoxy; and when R5, R8 and R9 are hydrogen, R6 and R7 are not methoxy.
  • In one embodiment, R1 is hydroxy, X is C(O) and R4 is
    Figure US20080075692A1-20080327-C00015
  • In one embodiment, R2, R3, R5, R6, R8 and R9 are each hydrogen and R7 is alkoxy (e.g., methoxy).
  • In another embodiment, R2, R3, R5, R7 and R8 are each hydrogen, and R6 and R9 are each alkyl (e.g., methyl).
  • In yet an other embodiment, R2, R3, R5, R8 are R9 are each hydrogen and R6 and R7 are each hydroxyl.
  • In a further embodiment, R2, R3, R5, R8 are R9 are each hydrogen and R6 and R7 are linked by —O—CH2—O— to form a ring.
  • In yet another embodiment, R2, R3, R5, R6 and R9 are each hydrogen, R7 is alkoxy (e.g., methoxy) and R8 is hydroxyl.
  • In another embodiment, R1 is hydroxy, X is C(O) and R4 is heteroaryl, such quinoline or substituted or unsubstituted thiophene (e.g., chlorothiophene).
  • In one embodiment, the present invention pertains, at least in part, to methods
  • for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula I, wherein the compound of formula I is:
    Figure US20080075692A1-20080327-C00016
  • In another embodiment, the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula II:
    Figure US20080075692A1-20080327-C00017
    wherein
  • R1′ is hydroxy or alkoxy;
  • Y is C(O);
  • n is 0 or an integer from 1 to 5;
  • R10 and R10′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino, heterocyclic or optionally joined to form a ring;
  • R11 is CR11′R11″R11′″, alkenyl, cycloalkyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, carbonylalkyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxy, halogen or
    Figure US20080075692A1-20080327-C00018
  • R11′ and R11″ are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxyl, halogen or R11′ and R11″ are optionally joined to form a ring;
  • R11′″ is alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or halogen;
  • R12 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic or optionally linked to R13 to form a ring;
  • R13 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or optionally linked to R12 or R14 to form a ring;
  • R14 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R13 or R15 to form a ring;
  • R15 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R14 or R16 to form a ring;
  • R16 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R15 to form a ring;
  • and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
  • provided that when R11 is
    Figure US20080075692A1-20080327-C00019
    R12, R13, R14, R15, and R16 are each not hydrogen; and provided when n is 2, R11 is
    Figure US20080075692A1-20080327-C00020
    and R10, R10′, R12, R15, and R16 are hydrogen, then R14 and R15 are not methoxy; and
    provided when n is 1, R11 is
    Figure US20080075692A1-20080327-C00021
    and R10, R10′, R13, R14, and R16 are hydrogen, then R12 and R15 are not methoxy.
  • In one embodiment, R1′ is hydroxyl, n is 5, R10 and R10′ are hydrogen and R11 is alkylcarbonyl.
  • In another embodiment, R1′ is hydroxyl, n is 2, R10 and R10′ are each hydrogen and R11 is CR11′R11″R11′″.
  • In a further embodiment, R11′ and R11″ are joined by —(CH2)5— to form a cyclohexyl ring and R11′″ is a substituted or unsubstituted heterocycle (e.g., chlorothiophene).
  • In one embodiment, R1′ is hydroxyl, n is 0 and R11 is
    Figure US20080075692A1-20080327-C00022
    In one embodiment, R13, R14, R15, and R16 are hydrogen and R12 is arylthioalkyl or alkoxy substituted aryloxy.
  • In another embodiment, R12, R14, R15 and R16 are hydrogen and R13 is a substituted or unsubstituted heterocycle, such as, for example, chromen-2-one, nitro-substituted pyrazole, or chloro-substituted pyrazole.
  • In yet another embodiment, R12, R13, R15 and R16 are hydrogen and R13 is alkoxy (e.g., ethoxy).
  • In a further embodiment, R12, R15 and R16 are hydrogen, and R13 and R14 are linked by —N(H)C(O)CH2S— to form a ring.
  • In yet another embodiment, R14, R15 and R16 are each hydrogen, and R12 and R13 are linked by —CH═C(CH3)O— to form a ring.
  • In one embodiment, R1′ is hydroxyl, n is 0 and R11 is a substituted or unsubstituted heterocycle (e.g., substituted aryl-substituted furan) or a substituted or unsubstituted cycloalkyl (e.g., tetrahydrobenzothiadiazole or dihydrobenzothiophenone).
  • In one embodiment, R1′ is hydroxyl, n is 1, R10 and R10′ are hydrogen and R11 is a substituted or unsubstituted cycloalkyl (e.g., dimethylcyclobutane carboxylic acid).
  • In another embodiment, R1′ is hydroxyl, n is 1, R10 and R10′ are hydrogen and R11 is
    Figure US20080075692A1-20080327-C00023
  • In one embodiment, R12, R13 and R16 are hydrogen, and R14 and R15 are linked by —O—CH2—O— to form a ring.
  • In another embodiment, R1′ is hydroxyl, n is 1, R10 and R10′ are hydrogen and R11 is a substituted or unsubstituted heterocycle, such as, for example substituted thiazolidinedione, substituted pyridinone or substituted pyrazole.
  • In yet another embodiment, R1′ is hydroxyl, n is 1, R10 and R10′ are hydrogen and R11 is a unsubstituted or substituted arylamino (e.g., trifluorothio-substituted arylamino).
  • In a further embodiment, R1′ is hydroxyl, n is 1, R10 and R10′ are hydrogen and R11 is unsubstituted or substituted arylthio (e.g., methoxyphenylthio) or unsubstituted or substituted heterocyclic thio, such as, for example, substituted triazolethio, substituted thiadiazolethio or substituted thiophenethio.
  • In another embodiment, R1′ is hydroxyl, n is 1, R10 and R10′ are hydrogen and R11 is R11 is CR11′R11″R11′″ and R11′ is hydrogen, R11″ is amino and R11′″ is alkoxy-substituted aryl.
  • In one embodiment, R1′ is hydroxyl, n is 1, R10 is hydrogen and R10′ is alkyl. In one embodiment, R10′ is isopropyl and R11 is substituted or unsubstituted arylthio, such as, for example, alkoxy-substituted phenylthio or alkoxy-substituted pyrimadinylthio.
  • In another embodiment, R10′ is ethyl and R11 is heteroarylamino (e.g., quinazolinylamino).
  • In yet another embodiment, R1′ is hydroxyl, n is 1, R10 and R10′ are linked by —(CH2)5— to form a cyclohexyl ring and R11 is heterocyclic substituted carbonylalkyl.
  • In one embodiment, the compounds of formula (II) do not include compounds wherein R1 is hydroxy, R10 is alkyl, e.g., ethyl, R10′ is hydrogen, n is 1, and R11 is arylamino, e.g., quinazolin-4-ylamino.
  • In one embodiment, the compounds of formula (II) do not include compounds wherein R1 is hydroxy, R10 is hydrogen, R10′ is alkyl, e.g., ethyl, n is 1, and R11 is arylamino, e.g., quinazolin-4-ylamino.
  • In another embodiment, the compounds of formula (II) do not include compounds wherein R1 is hydroxy, R10 and R10′ are each hydrogen, n is 1, and R11 is aryl amino (e.g., trifluorothio-substituted arylamino).
  • In another embodiment, the compounds of formula (II) do not include 2-(quinazolin-4-ylamino)butyric acid or [4-[(trifluoromethyl)sulfanyl]-anilino]-acetic acid.
  • In one embodiment, the present invention pertains, at least in part, to methods
  • for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula II, wherein the compound of formula II is:
    Figure US20080075692A1-20080327-C00024
    Figure US20080075692A1-20080327-C00025
    Figure US20080075692A1-20080327-C00026
  • as well as racemates and isolated enantiomers and diastereomers thereof.
  • In another embodiment, the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula III:
    Figure US20080075692A1-20080327-C00027
    wherein
  • R1″ is hydroxy or alkoxy;
  • Z is C(S), SO, SO2 or PO2;
  • m is 0 or an integer from 1-5;
  • R17 and R17′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R18 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxyl or halogen;
  • and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof.
  • In one embodiment, R1″ is hydroxyl, Z is SO2, m is 0, and R18 is disubstituted aryl substituted by, for example, nitro and fluoro.
  • In yet another embodiment, the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula III, wherein the compound of formula III is:
    Figure US20080075692A1-20080327-C00028
  • In another embodiment, the present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula:
    Figure US20080075692A1-20080327-C00029
  • In yet another embodiment, the invention pertains, at least in part, to a compound of formula I:
    Figure US20080075692A1-20080327-C00030
    wherein
  • R1 is hydroxy or alkoxy;
  • X is C(O), C(S), SO, SO2 or PO2;
  • R2 and R3 are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R4 is alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, halogen or
    Figure US20080075692A1-20080327-C00031
  • R5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R6 to form a ring;
  • R6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R5 or R7 to form a ring;
  • R7 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R6 or R8 to form a ring;
  • R8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R7 or R9 to form a ring;
  • R9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R8 to form a ring;
  • and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
  • provided that when R4 is
    Figure US20080075692A1-20080327-C00032
    R5, R6, R7, R8, and R9 are each not hydrogen; and when R6, R7, R8, and R9 are each hydrogen, R5 is not methoxy; and when R5, R7, R8, R9 are hydrogen, R6 is not methoxy; and when R5, R8 and R9 are hydrogen, R6 and R7 are not methoxy;
  • provided that the compound is not a compound of the formula:
    Figure US20080075692A1-20080327-C00033
  • The present invention also pertains, at least in part, to a compound of formula II:
    Figure US20080075692A1-20080327-C00034
    wherein
  • R1′ is hydroxy or alkoxy;
  • Y is C(O);
  • n is 0 or an integer from 1 to 5;
  • R10 and R10′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino, heterocyclic or optionally joined to form a ring;
  • R11 is CR11′R11″R11′″, alkenyl, cycloalkyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, carbonylalkyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxy, halogen or
    Figure US20080075692A1-20080327-C00035
  • R11′ and R11″ are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxyl, halogen or R11′ and R11″ are optionally joined to form a ring;
  • R11′″ is alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or halogen;
  • R12 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic or optionally linked to R13 to form a ring;
  • R13 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or optionally linked to R12 or R14 to form a ring;
  • R14 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R13 or R15 to form a ring;
  • R15 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R14 or R16 to form a ring;
  • R16 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R15 to form a ring;
  • and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
  • provided that when R11 is
    Figure US20080075692A1-20080327-C00036
    R12, R13, R14, R15, and R16 are each not hydrogen; and provided when n is 2, R11 is
    Figure US20080075692A1-20080327-C00037
    and R10, R10′, R12, R15, and R16 are hydrogen, then R14 and R15 are not methoxy; and
    provided when n is 1, R11 is
    Figure US20080075692A1-20080327-C00038
    and R10, R10′, R13, R14, and R16 are hydrogen, then R12 and R15 are not methoxy;
  • and provided that the compound is not a compound of:
    Figure US20080075692A1-20080327-C00039
    Figure US20080075692A1-20080327-C00040
  • In a further embodiment, the present invention pertains, at least in part, to a compound of formula III:
    Figure US20080075692A1-20080327-C00041
    wherein
  • R1″ is hydroxy or alkoxy;
  • Z is C(S), SO, SO2 or PO2;
  • m is 0 or an integer from 1-5;
  • R17 and R17′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
  • R18 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxyl or halogen;
  • and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
  • provided that the compound is not:
    Figure US20080075692A1-20080327-C00042
  • In one embodiment, the compounds of the invention do not include the compounds described in S. Casteneda et al., Blood Cells, Molecules, and Diseases, 35 (2005) 217-226.
  • The term “alkyl” includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkyl has 6 or fewer carbon atoms in its backbone (e.g., C1-C6 for straight chain, C3-C6 for branched chain), and more preferably 4 or fewer. Likewise, preferred cycloalkyls have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C1-C6 includes alkyl groups containing 1 to 6 carbon atoms.
  • Moreover, the term alkyl includes both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyls can be further substituted, e.g., with the substituents described above. An “alkylaryl” or an “arylalkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). The term “alkyl” also includes the side chains of natural and unnatural amino acids.
  • The term “aryl” includes groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiaozole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term “aryl” includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxophenyl, quinoline, isoquinoline, naphthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles”, “heterocycles,” “heteroaryls” or “heteroaromatics”. The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety, Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., tetralin).
  • The term “alkenyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
  • For example, the term “alkenyl” includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term alkenyl further includes alkenyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C2-C6 for straight chain, C3-C6 for branched chain). Likewise, cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C2-C6 includes alkenyl groups containing 2 to 6 carbon atoms.
  • Moreover, the term alkenyl includes both “unsubstituted alkenyls” and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • The term “alkynyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
  • For example, the term “alkynyl” includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term alkynyl further includes alkynyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C2-C6 for straight chain, C3-C6 for branched chain). The term C2-C6 includes alkynyl groups containing 2 to 6 carbon atoms.
  • Moreover, the term alkynyl includes both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • Unless the number of carbons is otherwise specified, “lower alkyl” as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure. “Lower alkenyl” and “lower alkynyl” have chain lengths of, for example, 2-5 carbon atoms.
  • The term “acyl” includes compounds and moieties which contain the acyl radical (CH3CO—) or a carbonyl group. It includes substituted acyl moieties. The term “substituted acyl” includes acyl groups where one or more of the hydrogen atoms are replaced by for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • The term “acylamino” includes moieties wherein an acyl moiety is bonded to an amino group. For example, the term includes alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.
  • The term “aroyl” includes compounds and moieties with an aryl or heteroaromatic moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl carboxy, etc.
  • The terms “alkoxyalkyl”, “alkylaminoalkyl” and “thioalkoxyalkyl” include alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms.
  • The term “alkoxy” includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups. Examples of substituted alkoxy groups include halogenated alkoxy groups. The alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, etc.
  • The term “amine” or “amino” includes compounds where a nitrogen atom is covalently bonded to at least one carbon or heteroatom. The term “alkyl amino” includes groups and compounds wherein the nitrogen is bound to at least one additional alkyl group. The term “dialkyl amino” includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. The term “arylamino” and “diarylamino” include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively. The term “alkylarylamino,” “alkylaminoaryl” or “arylaminoalkyl” refers to an amino group which is bound to at least one alkyl group and at least one aryl group. The term “alkaminoalkyl” or “alkyl aminoalkyl” refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
  • The term “amide” or “aminocarbonyl” includes compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group. The term includes “alkaminocarbonyl” or “alkylaminocarbonyl” groups which include alkyl, alkenyl, aryl or alkynyl groups bound to an amino group bound to a carbonyl group. It includes arylaminocarbonyl groups which include aryl or heteroaryl moieties bound to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group. The terms “alkylaminocarbonyl,” “alkenylaminocarbonyl,” “alkynylaminocarbonyl,” arylaminocarbonyl,” “alkylcarbonylamino,” “alkenylcarbonylamino,” alkynylcarbonylamino,” and “arylcarbonylamino” are included in term “amide.” Amides also include urea groups (aminocarbonylamino) and carbamates (oxycarbonylamino).
  • The term “carbonyl” or “carboxy” includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom. The carbonyl can be further substituted with any moiety which allows the compounds of the invention to perform its intended function. For example, carbonyl moieties may be substituted with alkyls, alkenyls, alkynyls, aryls, alkoxy, aminos, etc. Examples of moieties which contain a carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
  • The term “thiocarbonyl” or “thiocarboxy” includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom.
  • The term “ether” includes compounds or moieties which contain an oxygen bonded to two different carbon atoms or heteroatoms. For example, the term includes “alkoxyalkyl” which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group.
  • The term “ester” includes compounds and moieties which contain a carbon or a heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group. The term “ester” includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc. The alkyl, alkenyl, or alkynyl groups are as defined above.
  • The term “thioether” includes compounds and moieties which contain a sulfur atom bonded to two different carbon or hetero atoms. Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls, and alkthioalkynyls. The term “alkthioalkyls” include compounds with an alkyl, alkenyl, or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group. Similarly, the term “alkthioalkenyls” and alkthioalkynyls” refer to compounds or moieties wherein an alkyl, alkenyl, or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkynyl group.
  • The term “hydroxy” or “hydroxyl” includes groups with an —OH or —O−.
  • The term “halogen” includes fluorine, bromine, chlorine, iodine, etc. The term “perhalogenated” generally refers to a moiety wherein all hydrogens are replaced by halogen atoms.
  • The terms “polycyclyl” or “polycyclic radical” refer to two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, alkylaminoacarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkyl carbonyl, alkenylcarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • The term “heteroatom” includes atoms of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.
  • The term “ring” means cycloalkyl or aryl as these terms are used and defined herein.
  • The term “prodrug moiety” includes moieties which can be metabolized in vivo and moieties which may advantageously remain esterified or otherwise protected in vivo. Preferably, the prodrugs moieties are metabolized in vivo by esterases or by other mechanisms to hydroxyl groups or other advantageous groups. Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19). The prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters via treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides.
  • It will be noted that the structure of some of the compounds of this invention includes asymmetric carbon atoms, and thus may exist as racemic mixtures or as isolated isomeric forms. It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof.
  • The present invention pertains, at least in part, to methods for treating a blood disorder in a subject by administering to the subject an effective amount of a compound of the invention (e.g., a compound of Formula I, II, III or otherwise described herein, including isolated enantiomers or diastereomers).
  • The term “treating” includes curing as well as ameliorating at least one symptom of the state, disease or disorder, e.g., the blood disorder. Therefore, prevention of blood disorders or at least one symptom thereof is also contemplated herein.
  • The term “blood disorder” includes disorders which can be treated, prevented, or otherwise ameliorated by the administration of a compound of the invention, e.g., a compound of formula I, II, III or otherwise described herein). A blood disorder is any disorder of the blood and blood-forming organs. The term blood disorder includes nutritional anemias (e.g., iron deficiency anemia, sideropenic dysphasia, Plummer-Vinson syndrome, vitamin B12 deficiency anemia, vitamin B12 deficiency anemia due to intrinsic factor, pernicious anemia, folate deficiency anemia, and other nutritional anemias), myelodysplastic syndrome, bone marrow failure or anemia resulting from chemotherapy, radiation or other agents or therapies, hemolytic anemias (e.g., anemia due to enzyme disorders, anemia due to phosphate dehydrogenase (G6PD) deficiency, favism, anemia due to disorders of glutathione metabolism, anemia due to disorders of glycolytic enzymes, anemias due to disorders of nucleotide metabolism and anemias due to unspecified enzyme disorder), thalassemia α-thalassemia, β-thalassemia, δβ-thalassemia, thalassemia trait, hereditary persistence of fetal hemoglobin (HPFP), and unspecified thalassemias), sickle cell disorders (sickle cell anemia with crisis, sickle cell anemia without crisis, double heterozygous sickling disorders, sickle cell trait and other sickle cell disorders), hereditary hemolytic anemias (hereditary spherocytosis, hereditary elliptocytosis, other hemaglobinopathies and other specified hereditary hemolytic anemias, such as stomatocyclosis), acquired hemolytic anemia (e.g., drug-induced autoimmune hemolytic anemia, other autoimmune hemolytic anemias, such as warm autoimmune hemolytic anemia, drug-induced non-autoimmune hemolytic anemia, hemolytic-uremic syndrome, and other non-autoimmune hemolytic anemias, such as microangiopathic hemolytic anemia); aplastic anemias (e.g., acquired pure red cell aplasia (erythoblastopenia), other aplastic anemias, such as constitutional aplastic anemia and fanconi anemia, acute posthemorrhagic anemic, and anemias in chronic diseases), coagulation defects (e.g., disseminated intravascular coagulation (difibrination syndrome)), hereditary factor VIII deficiency (hemophilia A), hereditary factor IX deficiency (Christmas disease), and other coagulation defects such as Von Willebrand's disease, hereditary factor Xi deficiency (hemophilia C), purpura (e.g., qualitative platelet defects and Glanzmann's disease), neutropenia, agranulocytosis, functional disorders of polymorphonuclear neutrophils, other disorders of white blood cells (e.g., eosinophilia, leukocytosis, lymophocytosis, lymphopenia, monocytosis, and plasmacyclosis), diseases of the spleen, methemoglobinemia, other diseases of blood and blood forming organs (e.g., familial erythrocytosis, secondary polycythemia, essential thrombocytosis and basophilia), thrombocytopenia, infectious anemia, hypoproliferative or hypoplastic anemias, hemoglobin C, D and E disease, hemoglobin lepore disease, and HbH and HbS diseases, anemias due to blood loss, radiation therapy or chemotherapy, or thrombocytopenias and neutropenias due to radiation therapy or chemotherapy, sideroblastic anemias, myelophthisic anemias, antibody-mediated anemias, and certain diseases involving lymphoreticular tissue and reticulohistiocytic system (e.g., Langerhans' cell hystiocytosis, eosinophilic granuloma, Hand-Schuller-Christian disease, hemophagocytic lymphohistiocytosis, and infection-associated hemophagocytic syndrome).
  • In one embodiment, the compounds of formula I, II, III or otherwise described herein stimulate fetal hemoglobin production, hematopoiesis, erythropoiesis, myelopoiesis and/or neutrophil production upon administration to a subject for the treatment of a blood disorder.
  • In one embodiment, the compounds of formula I, II, III or otherwise described are administered to the subject for treatment of a blood disorder in combination with one or more cytokines. In one embodiment, the cytokine is selected from the group consisting of IL-3, GM-CSF, G-CSF, stem cell factor (SCF) and IL-6.
  • In the therapeutic methods of the invention, one or more compounds of the invention may be administered alone to a subject, or more typically a compound of the invention will be administered as part of a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral or other desired administration and which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof.
  • In another embodiment, the invention pertains, at least in part to a pharmaceutical composition of an effective amount of a compound of formula I, formula II, formula III, or
    Figure US20080075692A1-20080327-C00043
    and racemates, isolated enantiomers or diastereomers thereof, and a pharmaceutically acceptable carrier.
  • The language “pharmaceutically acceptable carrier” includes substances capable of being coadministered with the compound(s) of the invention and which allow both to perform their intended function, e.g., treat or prevent a blood disorder. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds of the invention.
  • The compounds of the invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of the compounds of the invention that are basic in nature are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and palmoate [i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)] salts. Although such salts must be pharmaceutically acceptable for administration to a subject, e.g., a mammal, it is often desirable in practice to initially isolate a compound of the invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The preparation of other compounds of the invention not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.
  • The compounds of the invention that are acidic in nature are capable of forming a wide variety of base salts. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of the invention that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmaceutically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines. The pharmaceutically acceptable base addition salts of compounds of the invention that are acidic in nature may be formed with pharmaceutically acceptable cations by conventional methods. Thus, these salts may be readily prepared by treating the compound of the invention with an aqueous solution of the desired pharmaceutically acceptable cation and evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, a lower alkyl alcohol solution of the compound of the invention may be mixed with an alkoxide of the desired metal and the solution subsequently evaporated to dryness.
  • The compounds of the invention and pharmaceutically acceptable salts thereof can be administered via either the oral, parenteral or topical routes. In general, these compounds are most desirably administered in effective dosages, depending upon the weight and condition of the subject being treated and the particular route of administration chosen. Variations may occur depending upon the species of the subject being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out.
  • The pharmaceutical compositions of the invention may be administered alone or in combination with other known compositions for treating blood disorders in a subject, e.g., a mammal. Preferred mammals include cats, dogs, pigs, rats, mice, monkeys, chimpanzees, baboons and humans. In one embodiment, the subject is suffering from a blood disorder. In another embodiment, the subject is at risk of suffering from a blood disorder.
  • The language “in combination with” a known composition is intended to include simultaneous administration of the composition of the invention and the known composition, administration of the composition of the invention first, followed by the known composition and administration of the known composition first, followed by the composition of the invention. Any of the therapeutically composition known in the art for treating blood disorders can be used in the methods of the invention.
  • The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the routes previously mentioned, and the administration may be carried out in single or multiple doses. For example, the novel therapeutic agents of this invention can be administered advantageously in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
  • For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • For parenteral administration (including intraperitoneal, subcutaneous, intravenous, intradermal or intramuscular injection), solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. For parenteral application, examples of suitable preparations include solutions, preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories. Therapeutic compounds may be formulated in sterile form in multiple or single dose formats such as being dispersed in a fluid carrier such as sterile physiological saline or 5% saline dextrose solutions commonly used with injectables.
  • Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin. Examples of methods of topical administration include transdermal, buccal or sublingual application. For topical applications, therapeutic compounds can be suitably admixed in a pharmacologically inert topical carrier such as a gel, an ointment, a lotion or a cream. Such topical carriers include water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils. Other possible topical carriers are liquid petrolatum, isopropylpalmitate, polyethylene glycol, ethanol 95%, polyoxyethylene monolauriate 5% in water, sodium lauryl sulfate 5% in water, and the like. In addition, materials such as anti-oxidants, humectants, viscosity stabilizers and the like also may be added if desired.
  • For enteral application, particularly suitable are tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or the like can be used wherein a sweetened vehicle is employed. Sustained release compositions can be formulated including those wherein the active component is derivatized with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.
  • It will be appreciated that the actual preferred amounts of active compounds used in a given therapy will vary according to the specific compound being utilized, the particular compositions formulated, the mode of application, the particular site of administration, etc. Optimal administration rates for a given protocol of administration can be readily ascertained by those skilled in the art using conventional dosage determination tests conducted with regard to the foregoing guidelines.
  • In general, compounds of the invention for treatment can be administered to a subject in dosages used in prior therapies. For example, a suitable effective dose of one or more compounds of the invention will be in the range of from 0.01 to 100 milligrams per kilogram of body weight of recipient per day, preferably in the range of from 0.1 to 50 milligrams per kilogram body weight of recipient per day, more preferably in the range of 1 to 20 milligrams per kilogram body weight of recipient per day. The desired dose is suitably administered once daily, or several sub-doses, e.g. 2 to 5 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule.
  • It will also be understood that normal, conventionally known precautions will be taken regarding the administration of the compounds of the invention generally to ensure their efficacy under normal use circumstances. Especially when employed for therapeutic treatment of humans and animals in vivo, the practitioner should take all sensible precautions to avoid conventionally known contradictions and toxic effects.
  • Furthermore, the invention also pertains to the use of a compound of formula I, II, III or a compound otherwise described herein for the preparation of a medicament. The medicament may include a pharmaceutically acceptable carrier and the compound is an effective amount, e.g., an effective amount to treat a blood disorder.
    • EXEMPLIFICATION OF THE INVENTION Example 1 Identification of Small Molecule Inducers of Fetal Hemoglobin
  • Small molecule inducers of fetal hemoglobin were identified using computer modeling techniques.
  • The pharmacophore was constructed with the TFIT module of the FLO molecular modeling software. It was assumed that the carboxylic acids would bind to the receptor in an analogous fashion, and therefore, the superposition of the carboxylic oxygens was biased by imposing a 5 kJ superimposition energy constraint. Five hundred iterations of TFIT were used in the calculations.
  • TFIT produced an ensemble of low energy superimposition. The superimposition with the tightest overlay was taken to be the initial pharmacophore template. This pharmacophore was tested to see if it could distinguish between active and inactive compounds. TFIT was first used to determine the best match between the pharmacophore and four compounds which had been identified as inactive in the β/γ-globin promoter driven reporter gene assay in previous studies.
  • The TFIT was next used to determine how well five additional compounds, which were active in the β/γ-globin promoter driven reporter gene assay would match the template. The template was used to design and select new compounds for testing. Compounds were selected from available compound data bases and evaluated by fitting them onto the template with TFIT.
  • The compounds generated from the modelling were tested in the β/γ-globin promoter driven reporter gene assay and were found to have statistically significant activity in the assay (Table 1). All of the compounds shown in Table 1 had a % y globin promoter induction (above untreated control) of between about 100%-200%.
    TABLE 1
    Compound
    Code Structure
    A
    Figure US20080075692A1-20080327-C00044
    B
    Figure US20080075692A1-20080327-C00045
    C
    Figure US20080075692A1-20080327-C00046
    D
    Figure US20080075692A1-20080327-C00047
    E
    Figure US20080075692A1-20080327-C00048
    H
    Figure US20080075692A1-20080327-C00049
    I
    Figure US20080075692A1-20080327-C00050
    J
    Figure US20080075692A1-20080327-C00051
  • Next, a “pseudo” receptor was constructed around the pharmacophore by refining the original pharmacophore template. A new template was constructed by adding two of the most active new compounds. The compounds were selected primarily for the additional structural information that they contained.
  • The “pseudo” binding site was construction using FLO. This “pseudo” binding site was composed of functional groups selected to form hydrogen bonds with the ligands, and functional groups that would mimic the hydrophobic surface of the binding site. A guanidinium group was selected form hydrogen bonds with the acidic groups of the ligands. A pyrrole group was used to mimic the binding site hydrogen bond donors. These groups were positioned around the template molecules and anchored to the chemically complimentary ligand atoms with a 10 kJ constraint. The “pseudo” program of FLO automatically filled the remaining volume with propane to mimic the binding site's hydrophobic surface. This structure was next subject to several rounds of dynamics.
  • Once the template atoms were removed, the shell of propanes, the pyrrole group and the guanidinium groups represented the receptor binding site. To ensure a moderate amount of binding site flexibility, the atoms of the binding site were allowed to move with a molecular mechanics force field and an additional flat well constraint [radius 0.5 Å, quadratic penalty 20 kJ/Å2] was imposed.
  • To test the “pseudo” binding site, twenty compounds (14 active and 6 inactive in the β/γ-globin promoter driven reporter gene assay) were docked into the binding site model using the docking module SDOCK+ of FLO+. For each docked conformation, FLO+ computed a predicted binding free energy using an empirical scoring function consisting of contact energy, hydrogen bonding energy, polar desolvation, bumping, internal energy and entropy. For the most active compounds, the predicted free energy (reported as pI or the −logKi), fell between 6.6 and 6.9, with hydrogen bonding energies between 7.4 and 8.9 kJ/mol. The pI values for the four inactive compounds ranged from 5.6 to 6.2 with hydrogen bonding energies between 5.6 and 7.0 kJ/mol. A combination of the pI and the hydrogen bonding energy was used to distinguish between active and inactive compounds.
  • Compounds for screening were then selected from a database of 13,000 commercially available compounds. Only molecules with an acid group and less that 24 heavy atoms were chosen, resulting in 630 compounds. These compounds were docked into the binding site using SDOCK+. The binding modes were scored using FLO+ and the best 10 conformations for each compound were retained for visual inspection.
    TABLE 2
    % Υ globin promoter
    Compound induction (above
    Code Structure untreated control
    F
    Figure US20080075692A1-20080327-C00052
         		***
    K
    Figure US20080075692A1-20080327-C00053
         		*
    M
    Figure US20080075692A1-20080327-C00054
         		**
    N
    Figure US20080075692A1-20080327-C00055
         		***
    O
    Figure US20080075692A1-20080327-C00056
         		*
    P
    Figure US20080075692A1-20080327-C00057
         		***
    Q
    Figure US20080075692A1-20080327-C00058
         		**
    R
    Figure US20080075692A1-20080327-C00059
         		***
    S
    Figure US20080075692A1-20080327-C00060
         		**
    T
    Figure US20080075692A1-20080327-C00061
         		**
    V
    Figure US20080075692A1-20080327-C00062
         		**
    W
    Figure US20080075692A1-20080327-C00063
         		**
    X
    Figure US20080075692A1-20080327-C00064
         		**
    Y
    Figure US20080075692A1-20080327-C00065
         		**
    Z
    Figure US20080075692A1-20080327-C00066
         		**
    AA
    Figure US20080075692A1-20080327-C00067
         		**
    AB
    Figure US20080075692A1-20080327-C00068
         		**
    AC
    Figure US20080075692A1-20080327-C00069
         		**
    AD
    Figure US20080075692A1-20080327-C00070
         		**
    AE
    Figure US20080075692A1-20080327-C00071
         		**
    AF
    Figure US20080075692A1-20080327-C00072
         		*
    AG
    Figure US20080075692A1-20080327-C00073
         		**
    AH
    Figure US20080075692A1-20080327-C00074
         		**
    AI
    Figure US20080075692A1-20080327-C00075
         		**
    AJ
    Figure US20080075692A1-20080327-C00076
         		**
    AK
    Figure US20080075692A1-20080327-C00077
         		**

    Using the pl and hydrogen bonding energy as criteria, 30 compounds were selected for in vitro testing. The scores for these compounds ranged for pl 5.1 (hydrogen bonding energy of −8.1 kJ/mol) to pl 8.8 (hydrogen bonding of 9.4 kJ/mol). Twenty six of these compounds were acquired and tested. Table 2 shows the results of the β/Υ-globin promoter driven reporter gene assay for the twenty-six compounds. ‘*’ indicates a 80-100% increase; ‘**’ indicates a 100%-
    #200% increase; and ‘***’ indicates an over 200% increase of Υ globin promoter induction over untreated controls.
    • Example 2 IN Vitro Stimulation of Fetal Globin mRNA Expression
  • This example demonstrates that the test compounds predicted to be active by reporter gene assays and molecular modeling produce a significant increase in fetal (gamma) globin mRNA in cells cultured in vitro. Furthermore, the concentrations required were significantly lower (5-40 micromolar) than concentrations required for prior generation inducers (100-200 micromolar), making these compounds more suitable for therapeutic and pharmacologic compositions
  • γ-globin mRNA was analyzed in control and treated erythroid colonies cultured from cord blood, by RT-PCR.
  • Induction (increase) in fetal globin mRNA compared to untreated control levels with each compound is shown in Table 3 below. The R enantiomer of compound Y demonstrated fetal globin inducing action, whereas the S enantiomer did not induce fetal globin in 2 of (the same) 3 cultures.
    TABLE 3
    Increase in Fetal Globin mRNA
    Concentration Mean change
    required, above control, No. of Positive
    Compound micromolar % responses
    M 5 70 4/6
    P 20 86 6/6
    2-methyl-1- 5 46 6/6
    benzofuran-4-
    carboxylic acid
    V 5 50 6/6
    W 40 368 5/6
    3-(5- 30 50
    chlorothien-3-
    yl)acrylic acid
    Y racemic mix 5 20 1/3
    Y + R 5 67 2/3
    Y − S 5 −2 1/3
  • These levels of fetal globin induction are higher than the induction by previously reporter inducing agents, and occur at lower concentrations, i.e., these agents have higher potency.
  • In a related study, the relative luciferase reporter gene induction, γ-globin gene induction, and F cell production was tested for several of the candidate compounds. The relative in vitro γ-globin gene reporter stimulation for the tested compounds was as follows: compound P>M>W=R=Y. The relative in vitro γ-globin gene induction for the tested compounds was as follows: P>R=M>Y>W>. The relative in vitro F-cell production was as follows: W>Y>R>M>P. The relative potency for F-cell production was as follows: R>M>Y>P>W.
    • Example 3 Effects on Erythroid and Myeloid Cell Growth In Vitro
  • This example demonstrates that the test compounds predicted to be active by reporter gene assays and molecular modeling produce a significant increase in numbers of erythroid and myeloid colonies or proportion of cells expressing fetal globin in in vitro cultured cells from a variety of sources under a variety of culture conditions. Similar to other in vitro tests described herein, the concentrations required for these biological effects were significantly lower (5-40 micromolar) than concentrations required for prior generation inducers (100-200 micromolar), making these compounds more suitable for therapeutic and pharmacologic compositions.
  • Compounds predicted in the molecular model to be γ-globin inducers were evaluated in a series of assays for activity in 1) stimulating activity from the fetal globin gene promoter, (the action which can ameliorate sickle cell disease and beta thalassemia), and 2) for any effects on stimulating erythroid or myeloid cell growth and proliferation, the action which can treat blood cell deficiencies.
  • Erythroid burst-forming units (BFU-E) (erythroid progenitors) and colony-forming units granulocyte-macrophage (CFU-GM) (myeloid colonies) were cultured in semi-solid or in two-phase suspension media, with or without hematopoietic growth factors at high levels (e.g., erythropoietin at 3 U/ml) or reduced levels (BFU-E cell proliferation was evaluated by enumeration in colonies developing in the presence of reduced amounts of erythropoietin (0.5 U/ml) rather than 3 U (or 3000 mU)/ml, which is standard for these experimental systems), from cord blood or the peripheral blood of several types of humans. Experiments were carried out on samples derived from 1) β-thalassemia patients who expressed variable levels of fetal globin at baseline (and in untreated control cultures) and represent a variety of potential individual responses, 2) from normal umbilical cord blood samples, which express 40-50% fetal globin at baseline (and in untreated control cultures), 3) from CD34+ cells isolated from normal adult peripheral blood, which expressed low levels of fetal globin in untreated control cultures and at baseline; and 4) from peripheral blood of patients with sickle cell disease who were receiving treatment with hydroxyurea. These biological samples provide a range of potential difficulty in stimulating fetal globin expression in human patients.
  • Experiment 1: Hematopoietic colonies were enumerated with or without (+/−) the test compounds, and compared to colonies which developed in the presence of hematopoietic growth factors alone from the same subject (untreated control colonies), and proportions of cells expressing fetal globin (F-cells) were analyzed by FACScan analysis. The compounds M, N, P, R, T, 2-methyl-1-benzofuran-4-carboxylic acid, V, W, X, Y, Z, F and 3-(5-chlorothien-3-yl)acrylic acid, all resulted in significant increases in the proportion of F-cells above the percentage of F-cells in untreated controls, at the same low concentrations as required for fetal globin mRNA induction and increases in erythroid colony numbers with the compounds.
  • Experiment 2: Erythroid colonies were cultured from patients with beta thalassemia, either without any test compounds (Control), only an optimal panel of hematopoietic growth factors, or with one of the test compounds M, P, T, 2-methyl-1-benzofuran-4-carboxylic acid, V, W, X, Y, AK, AC, or AI. All of the listed test compounds increased the number of colonies as compared to the matched control cultures that were grown with an optimal panel of growth factors alone. Colony numbers were increased above the control cultures (% BFU-E/Control) by anywhere from 25% to 230%. Each of the listed test compounds was tested in at least 5 different patients' blood and the differences were statistically signficant.
  • In a related study, BFU-E cultured from cord blood, was tested with or without compound M, P, R, T, W, Y, Z, AI, F, or 3-(5-chlorothien-3-yl)acrylic acid. The test compounds all induced increased numbers of colonies as compared to the controls. In this study the test compounds resulted in 50-250% more colonies than in control cultures from the same source.
  • Experiment 3: Representative novel compounds M, W, X, Y, and AI also stimulated production of myeloid colonies compared to control, untreated myeloid colonies from the same individual. Control colonies were established in cultures with no added growth factors to support myelopoiesis, in Iscove's Modified Dulbecco's Media (IMDM) methylcellulose media with charcoal-absorbed fetal bovine serum, beta mercaptoethanol, BSA. A 30-75% increase in de novo myeloid colonies was observed in cord blood cultured with the novel compounds at the same concentrations as required for increases in erythroid colonies.
  • Experiment 4: Erythroid cells cultured from adult blood are low-HbF expressing and are the most difficult to alter with regard to globin expression. This experiment analyzed erythroid cells cultured from adult blood in the presence or absence of representative test compounds.
  • Erythroid cells were generated by culturing purified CD34+ cells in Flt-3 ligand, stem cell factor (SCF) and IL-3 for seven days followed by growth in EPO for 14 days. For treatment, cells were cultured as above in a T75 flask then split into multiple flasks on day 8 and treatment with the test compounds was begun. Compound P or other test compounds were diluted from stock solutions with the microliter volumes of stock added to each culture flask for final working concentrations. Cells were enumerated every two days by hemacytometer count. RNA was harvested from 106 cells every two days using RNeasy Plus Mini Kit (Qiagen) and qRT-PCR performed using IQ SybrGreen Supermix on an Opticon Monitor instrument (MJ Research). Samples were assayed in triplicate and raw data from the instrument was analyzed using a method suggested by Larionov et al. with beta-actin and G3PD assayed as controls (housekeeping genes). Separation of hemoglobins was performed by cation exchange HPLC using a 35×4.6 mm; 3 mm PolyCAT A column (Nest Group) as described previously by Cheryl Rognerud and Ching-Nan Ou, and outlined by the column manufacturer.
  • QPCR primers were designed using known sequences for α-globin, β-globin, γ-globin, β-actin and B3PD. Primers were designed to span at least one exon.
  • The results showed that erythroid cells peaked at day 12-14 of the erythroid phase. Cell counts were increased with 20 microM compound P as compared to control cells cultured with erythropoietin alone. Comparison of compound P at different doses showed that there was no effect on production/expression of alpha globin, but there was a reciprocal decrease in production of beta globin concomitantly with increases in fetal globin mRNA expression at the same doses. The activity was specific for inducing gamma (fetal) globin with reciprocal decrease in beta globin. Hemoglobin F protein levels increased in a compound P dose-dependent manner with a 19-fold increase in expression of fetal globin produced at 100 micromolar compound P as compared to untreated control cultures from the same subject with just one cycle of erythroid differentiation.
  • Experiment 5: In an additional study, comparative growth of erythroid (red blood cell) colonies cultured from cord blood samples was evaluated with the addition of growth factors alone or with the addition of test compounds.
  • Comparative growth of erythroid colonies cultured from cord blood samples under conditions with standard growth factors alone (Control), or with addition of test compounds or arginine butyrate (AB) (AB results in reduced colony numbers). Control and test cultures were established from the same samples with the same growth factors (EPO and II-3) with addition of test compounds. The compounds tested were M, P, R, T, W, Y, Z, AI, F and 3-(5-chlorothien-3-yl)acrylic acid. Two compounds previously shown as positive proliferative agents were included for comparison. All compounds tested, except compound AI and 3-(5-chlorothien-3-yl)acrylic acid, resulted in an increase in red blood cell colony numbers by at least 25% above control numbers and was statistically significant. These results indicate that the test compounds stimulate red blood cell production even in conditions of maximal growth factors and in the absence of anemia.
  • Experiment 6: Erythroid colonies from the peripheral blood of 4 patients with sickle cell disease who were receiving treatment with Hydroxyurea (HU), a chemotherapeutic agent which suppresses marrow growth and reduces red blood cell production, were cultured alone or with added test compounds M, P, 2-methyl-1-benzofuran-4-carboxylic acid, V, W, Y (racemic mixture) or AI. L-arginine was added as a neutral control, and had no effect on numbers of erythroid colonies. Addition of arginine butyrate (AB), phenylacetate (PA), and hydroxyurea (HU) resulted in decreased numbers of erythroid colonies compared to control conditions.
  • As summarized in Table 5 below, addition of the test compounds M, P, 2-methyl-1-benzofuran-4-carboxylic acid, V, W, Y (racemic mixture) or AI (at the concentrations shown in the Table 5) resulted in an increase in numbers of erythroid colonies of at least 25% above control conditions. Compounds marked with a * are significantly different. 2-methyl-1-benzofuran-4-carboxylic acid and compound V require additional samples for statistical evaluation, but had positive effects in 3/3 different patients' cultures. These findings indicate that the test compounds stimulate erythroid cell production particularly in conditions of anemia and bone marrow suppression.
    TABLE 5
    Erythroid Colony Growth from Sickle Cell Patients +/−
    Test Compounds % Change from control conditions
    with growth factors alone
    Number with
    Concentration, % Change effects/
    Compound micromolar from Control No effect P-value
    L-arginine 150 −3 3/5 0.6, not
    (neutral significant
    control)
    AB (arginine 100 −29 5/6 0.019
    butyrate)
    PA 100 −10 5/7 0.2
    Phenylacetate
    M* 1 +58 5/5 0.035
    P* 100 +32 7/7 0.016
    2-methyl-1- 10 +51 3/3 0.1
    benzofuran-
    4-carboxylic
    acid
    V 10 +35 3/3 0.09
    W* 40 +47 5/5 0.048
    Y racemic 50 +47 6/7 0.024
    mix*
    Al* 30 +51 4/5 0.04
    Hydroxyurea 20 −33 2/2 0.58
  • In summary, the experiments described in this example show that representative test compounds produce a significant increase in numbers of erythroid and myeloid colonies or proportion of cells expressing fetal globin in in vitro cultured cells derived from a variety of sources under culture conditions relevant to blood conditions including anemia, sickle cell anemia and beta thalassamia.
    • Example 4 In Vivo Efficacy in a Non-Human Primate Model
  • Compounds P, Y and W were evaluated in a non-human primate model to evaluate functional activity of these candidate compounds in stimulating either fetal globin expression or production of blood cells. As described below, these studies demonstrated potent in vivo activity of the compounds for inducing fetal globin expression and production of blood cells.
  • Juvenile baboons were catheterized with venous and arterial catheters, and were phlebotomized a set amount of blood daily to maintain anemia with a hemoglobin level of 7.0-7.5 g/dl, from a baseline normal hemoglobin level of (12-13 g/dl). Normal saline was infused to replace the amount of blood withdrawn. This degree of phlebotomy exchanges the blood volume every 10-20 days.
  • Fetal globin mRNA was analyzed at baseline anemia before and following administration of test compounds. Globin chain protein synthesis confirmed the mRNA findings.
  • Following establishment of the stable level of anemia, a test compound was administered once/day, either intravenously or orally, and blood was withdrawn through the arterial catheter for analysis of globin mRNA or for analysis of the test compound in the plasma by HPLC-MS. Pharmacokinetic profiles were established from the plasma levels and oral bioavailability (comparing area under the curve between IV and oral plasma levels) was determined for the test compounds.
  • Pharmacokinetic profiles of compounds M (100 mg/kg), P (25 mg/kg), 2-methyl-1-benzofuran-4-carboxylic acid (100 mg/kg), W (100 mg/kg), and Y (10 mg/kg) indicated that these compounds persist well above therapeutic levels for >8 hours after tolerable single oral doses. Human equivalent doses are 20-50% of doses in baboons. Unusually low doses of compound P (25 mg/kg) and of compound Y (10 mg/kg), respectively, were required. Previously reported compounds typically require 100-500 mg/kg/dose for induction of fetal globin. Compound Y in particular also does not produce an undesirable high initial burst level and persists for greater than 24 hours. The human equivalent doses are 10-20% of the baboon dose. Thus for compound Y, the human equivalent dose would be 1-2 mg/kg, a dose highly favorable for a pharmaceutical composition.
  • Compound P and compound Y treatment in anemic baboons induced 3 to 6-fold γ-globin mRNA expression. Prior generation compounds typically induce fetal globin mRNA only by 2-fold.
  • In a further in vivo study, compounds AK, Y and M were evaluated in a baboon and demonstrated significant increases in fetal globin expression at tolerable low doses. As shown in the previous Examples, these 3 compounds all stimulated erythroid cell proliferation in vitro and have favorable pharmacokinetic profiles after oral administration. The compounds were administered to an anemic baboon and studied for pharmacodynamic effects on induction of fetal globin, which is known to ameliorate the pathology of sickle cell anemia and beta thalassemia.
  • In anemic Baboon 5002, baseline fetal globin mRNA, assayed by RNAse protection, was 26% of non-alpha globin. With treatment with compound Y at 5 mg/kg/dose, fetal globin mRNA increased to 48% of non-alpha globin, an 85% increase over the baseline level. Treatment with compound AK at 50 mg/kg induced a 51% fetal globin mRNA increase, a 96% increase over the baseline level. Compound M treatment at 40 mg/kg induced a 67% fetal globin mRNA increase, a 257% increase over the baseline level. The human equivalent dose is 20% of these doses, or 1 mg/kg, 10 mg/kg, or 8 mg/kg respectively. Thus, these 3 compounds are highly suitable for pharmaceutical compositions at doses that human patients can readily tolerate.
  • In a related study, compound P was evaluated in a phlebotomized, anemic baboon showing no baseline expression of fetal globin and 100% of globin expression as beta globin. Treatment with compound P resulted in an induction of 7% fetal globin and a concomitant reduction in beta globin expression.
  • These findings show that these compounds are excellent candidates for treatment of the beta hemoglobinopathies and thalassemias.
    • Example 5 Induction of Fetal Globin Expression in an In Vivo Transgenic Mouse Model
  • This example demonstrates that compound W increases expression of human fetal globin mRNA expression and hematocrit in a transgenic mouse model.
  • Transgenic mice containing the human fetal globin gene and a micro-Locus Control Region (LCR) received no treatment (controls) or were treated with test compounds and γ-globin mRNA was analyzed by RT-PCR. Compound W was administered to mice transgenic for the micro-LCR-201 gamma-globin gene promoter, by IP injection once/day for 5 days/week for 2 weeks, and gamma-globin mRNA was assayed by qPCR. Hematocrit was analyzed once per week. A significant difference in expression of human fetal globin mRNA and in hematocrit between Control and compound W-treated mice was found in initial experiments as summarized in Table 4 below.
    TABLE 4
    γ-Globin Induction by Compound W in Transgenic Mice
    γ-globin mRNA/S16
    Study Treatment (mean relative units) Hematocrit
    None 1508 51 +/− 0.45
    Compound W 3418 57 +/− 3
    p-value, paired t-test <0.05 <0.05
    • Example 6 Synthesis of Compound Y Enantiomers
  • Figure US20080075692A1-20080327-C00078
  • Cesium thiobenzoate. To a solution of thiobenzoic acid (50.0 g, 361.8 mmol) in methanol (362 mL) was added Cs2CO3 (130 g, 398 mmol) in portions over 5 min. The resulting mixture was stirred 10 min until all solids were dissolved. The resulting solution was concentrated on the rotovap. The solid residue was diluted with 500 mL of acetone and the white solid (CsHCO3) was filtered off. This process was repeated two times to ensure all CsHCO3 was removed. The acetone was then concentrated to afford cesium thiobenzoate (Strijtveen, B.; Kellogg, R. M. J. Org. Chem. 1986, 51, 3664) as a yellow solid (81.5 g, 83%); 1H NMR (300 MHz, CD3OD) δ 7.25-7.38 (m, 3H), 8.09 (dd, J=1.4, 8.2 Hz, 2H).
    Figure US20080075692A1-20080327-C00079
  • (R)-2-Benzoylthio-3-methylbutanoic acid. To a solution of (S)-(−)-2-bromo-3-methylbutyric acid (4.20 g, 23.2 mmol) in DMF (41 mL) was added cesium thiobenzoate (6.08 g, 22.5 mmol). The mixture was stirred at rt for 20 h. The resulting solution was diluted with ether (200 mL) and washed with H2O (4×40 mL). The ethereal layer was dried (Na2SO4), and concentrated. The crude residue was recrystallized from hexanes to afford (R)-2-benzoylthio-3-methylbutanoic acid as a pale yellow solid (4.05 g, 75%); 1H NMR (300 MHz, CDCl3) δ 1.09 (d, J=7.4 Hz, 3H), 1.11 (d, J=7.4 Hz, 3H), 2.40 (m, 1H), 4.37 (d, J=5.9 Hz, 1H), 7.45 (t, J=7.4 Hz, 2H), 7.57 (t, J=7.4 Hz, 1H), 7.97 (d, J=7.4 Hz, 2H), 11.9 (br s, 1H); 13C NMR (75 MHz, CDCl3) δ 19.8, 20.6, 30.5, 53.1, 127.6, 128.8, 133.9, 136.3, 177.9, 190.3; IR (neat) 3100, 2967, 1709, 1669 cm−1; [α]D 22=+95.6 (C1, CH2Cl2). All spectral data was identical to that previously published (Strijtveen, B.; Kellogg, R. M. J. Org. Chem. 1986, 51, 3664).
    Figure US20080075692A1-20080327-C00080
  • (S)-2-Benzoylthio-3-methylbutanoic acid. To a solution of (R)-(+)-2-bromo-3-methylbutyric acid (4.20 g, 23.2 mmol) in DMF (41 mL) was added cesium thiobenzoate (6.08 g, 22.5 mmol). The mixture was stirred at rt for 20 h. The resulting solution was diluted with ether (200 mL) and washed with H2O (4×40 mL). The ethereal layer was dried (Na2SO4), and concentrated. The crude residue was recrystallized from hexanes to afford (S)-2-benzoylthio-3-methylbutanoic acid as a pale yellow solid (3.89 g, 72%); 1H NMR (300 MHz, CDCl3) δ 1.09 (d, J=7.4 Hz, 3H), 1.11 (d, J=7.4 Hz, 3H), 2.40 (m, 1H), 4.37 (d, J=5.9 Hz, 1H), 7.45 (t, J=7.4 Hz, 2H), 7.57 (t, J=7.4 Hz, 1H), 7.97 (d, J=7.4 Hz, 2H), 12.0 (br s, 1H); 13C NMR (75 MHz, CDCl3) δ 19.8, 20.6, 30.5, 53.1, 127.6, 128.8, 133.9, 136.3, 177.9, 190.3; IR (neat) 3100, 2967, 1709, 1669 cm−1; [α]D 22=−94.2 (c 1, CH2Cl2).
    Figure US20080075692A1-20080327-C00081
  • (R)-2-Mercapto-3-methylbutanoic acid. To a solution of (R)-2-benzoylthio-3-methylbutanoic acid (4.05 g, 17.0 mmol) in CH2Cl2 (68 mL) was added 3 M aqueous NH4OH (68 mL). The mixture was stirred at rt for 3 h. The resulting solution was diluted with 2 M aqueous KOH (68 mL) and washed with CH2Cl2 (6×70 mL) to remove the benzamide. The aqueous layer was then acidified to pH 2 with concentrated aqueous HCl and extracted with CH2Cl2 (4×70 mL). The organic extracts were dried (Na2SO4) and concentrated to afford (R)-2-mercapto-3-methylbutanoic acid as a white solid (2.10 g, 92%); 1H NMR (300 MHz, CDCl3) δ 1.05 (d, J=6.7 Hz, 3H), 1.09 (d, J=6.7 Hz, 3H), 1.96 (d, J=9.7 Hz, 1H), 2.07 (m, 1H), 3.13 (dd, J=8.1, 9.7 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 19.3, 20.8, 32.6, 48.8, 179.8; IR (neat) 3100, 2966, 1705 cm−1; [α]D 22=+41.0 (c 1, ether).
    Figure US20080075692A1-20080327-C00082
  • (S)-2-Mercapto-3-methylbutanoic acid. To a solution of (S)-2-benzoylthio-3-methylbutanoic acid (3.89 g, 16.3 mmol) in CH2Cl2 (65 mL) was added 3 M aqueous NH4OH (65 mL). The mixture was stirred at rt for 3 h. The resulting solution was diluted with 2 M aqueous KOH (65 mL) and washed with CH2Cl2 (6×65 mL) to remove the benzamide. The aqueous layer was then acidified to pH 2 with concentrated aqueous HCl and extracted with CH2Cl2 (4×65 mL). The organic extracts were dried (Na2SO4) and concentrated to afford (S)-2-mercapto-3-methylbutanoic acid as a white solid (2.00 g, 91%); 1H NMR (300 MHz, CDCl3) δ 1.05 (d, J=6.7 Hz, 3H), 1.09 (d, J=6.7 Hz, 3H), 1.96 (d, J=9.7 Hz, 1H), 2.07 (m, 1H), 3.13 (dd, J=8.1, 9.7 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 19.3, 20.8, 32.6, 48.8, 179.8; IR (neat) 3100, 2966, 1705 cm−1; [α]D 22=−40.2 (c 1, ether).
    Figure US20080075692A1-20080327-C00083
  • (R)-Compound Y. To (R)-2-mercapto-3-methylbutanoic acid (2.10 g, 15.6 mmol) was added aqueous NaOH (1.0 M in H2O, 37.6 mL, 37.6 mmol). The mixture was stirred at rt for 10 min. The resulting solution was cooled to 0° C., diluted with DMF (20 mL), and 4,6-dimethoxy-2-(methylsulfonyl)pyrimidine (3.42 g, 15.6 mmol) in DMF (10 mL) was added (a slightly modified procedure of Fukuda, S.; Akiyoshi, Y.; Hori, K. J. Org. Chem. 1999, 64, 4768; 4,6-dimethoxy-2-(methylsulfonyl)pyrimidine is commercially available from Aldrich). The mixture was warmed to rt and stirred for 1 h. The resulting solution was quenched with 2 M HCl and extracted with ethyl acetate. The combined extracts were washed with brine, dried (Na2SO4) and concentrated. Purification by silica gel chromatography (gradient column, ethyl acetate-hexanes, 1:5→1:1→1:0) afforded (R)-compound Y as white crystals (3.77 g, 88%); 1H NMR (300 MHz, CDCl3) δ 1.15 (d, J=6.4 Hz, 3H), 1.17 (J=6.4 Hz, 3H), 2.41 (m, 1H), 3.89 (s, 6H), 4.16 (d, J=5.9 Hz, 1H), 5.78 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 20.1, 20.9, 30.1, 54.4, 54.9, 86.5, 169.4, 170.9, 177.9; IR (neat) 3050, 2964, 1710, 1581, 1557 cm−1; [α]D 22=+127.2 (c 1, CH2Cl2).
    Figure US20080075692A1-20080327-C00084
  • (S)-Compound Y. To (S)-2-mercapto-3-methylbutanoic acid (2.00 g, 14.9 mmol) was added aqueous NaOH (1.0 M in H2O, 35.8 mL, 35.8 mmol). The mixture was stirred at rt for 10 min. The resulting solution was cooled to 0° C., diluted with DMF (20 mL), and 4,6-dimethoxy-2-(methylsulfonyl)pyrimidine2,3 (3.25 g, 14.9 mmol) in DMF (10 mL) was added. The mixture was warmed to rt and stirred for 1 h. The resulting solution was quenched with 2 M HCl and extracted with ethyl acetate. The combined extracts were washed with brine, dried (Na2SO4) and concentrated. Purification by silica gel chromatography (gradient column, ethyl acetate-hexanes, 1:5→1:1→1:0) afforded (S)-compound Y as white crystals (3.65 g, 90%); 1H NMR (300 MHz, CDCl3) δ 1.15 (d, J=6.4 Hz, 3H), 1.17 (J=6.4 Hz, 3H), 2.41 (m, 1H), 3.89 (s, 6H), 4.16 (d, J=5.9 Hz, 1H), 5.78 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 20.1, 20.9, 30.1, 54.4, 54.9, 86.5, 169.4, 170.9, 177.9; IR (neat) 3050, 2964, 1710, 1581, 1557 cm−1; [α]D 22=−127.3 (c 1, CH2Cl2).
    • Example 7 Selective Activity of the S Enantiomer of Compound Y
  • Compound Y exists naturally in a racemic mixture, and has the highly favorable PK properties described above. The experiments described herein demonstrate that the S enantiomer of compound Y stimulates erythroid cell proliferation significantly, while the R enantiomer does not stimulate cell proliferation. The R enantiomer of compound Y has activity in stimulating fetal globin expression (see Table 3).
  • The proliferative activity of compound Y-S enantiomer was tested in vitro in erythroid colonies cultured from peripheral blood of 3 sources of individuals: sickle cell anemia patients who were taking Hydroxyurea and have suppression of their endogenous erythropoiesis, a normal adult subject, and two cord blood samples. The erythroid cultures were established with low concentrations of Erythropoietin (0.5 U/ml) alone and with one or the other enantiomer of compound Y or the racemic mixture, or with high concentrations of EPO (3 Units/ml, =3000 mU/ml, 100-fold the normal physiologic concentration).
  • The cultures established in high EPO produced 25-45% (mean 35%) more colonies than the cultures established with the racemic mix in low EPO or the R enantiomer in low EPO. Addition of the S— enantiomer of compound Y at the same concentration resulted in a mean of 45% more erythroid colonies than in the racemic mixture (range 38-50%). Thus, the S enantiomer demonstrates the activity of stimulating proliferation of erythroid colonies in vitro.
    • Example 8 Molecular Mechanism of Action
  • Without being bound by theory, it is thought that the compounds described herein operate by a novel and highly specific molecular mechanism of action as elucidated further below.
  • The erythroid kruppel-like factor, EKLF, is an essential transcription factor for mammalian beta-like globin gene switch, and it specifically activates transcription of the adult beta-globin gene through binding of its zinc fingers to the promoter. It has been shown that transcription factor EKLF is required for activation of the gamma globin gene by the compounds described herein. EKLF was previously considered to activate primarily the beta (adult) globin gene. Transcription factor EKLF is actively recruited to the gamma-globin gene promoter by the compounds described herein. The human SWI/WNF complex is a ubiquitous multimeric complex that regulates gene expression by remodeling nucleosomal structure in an ATP-dependent manner. The SWI/SNF complex contains one of two core ATPases, BRG1 or BRM. These complexes can interact with sequence specific transcription factors to either promote or repress target gene activation, dependent on promoter context and complex content. The SWI/SNF complex chromatin-modifying core ATPase Brg1 is required for gamma globin induction by the compounds described herein. Brg1, the co-activator SWI/SNF complex chromatin-modifying ATPase, is actively recruited to the gamma-globin promoter by the compounds described herein, and this recruitment is dependent upon the presence of EKLF.
  • Two compounds were evaluated, compound P and W. Exposure of primary erythroid cells to the high-potency inducer, compound P, resulted in displacement of a repressor complex of HDAC3, NCoR, specifically from the fetal globin gene promoter, with local hyperacetylation of the promoter. Further, exposure to the compound induced recruitment of erythroid kruppel-like factor (EKLF) and Brahma-related gene 1 (Brg1) ATPase proteins to the gamma-globin gene promoter, resulting in selective transcriptional activation of the gamma globin gene. This is a selective effect on the fetal (gamma globin) gene promoter, without generalized widespread epistatic effects or any effects on the beta globin promoter, as other agents tend to cause. The transcription factor EKLF and the remodeling complex Brg1 and Pol II became bound to the promoter in association with gene activation. In contrast, there were no effects on the beta globin gene promoter. These compounds therefore produce highly specific activating effects solely on the globin gene promoter which would be beneficial to induce for therapy of the beta globin gene disorders, and provide a targeted molecular activity.
    • EQUIVALENTS
  • Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of the present invention and are covered by the following claims. The contents of all references, patents, and patent applications cited throughout this application are hereby incorporated by reference. The appropriate components, processes, and methods of those patents, applications and other documents may be selected for the present invention and embodiments thereof.

Claims (77)

1. A method for treating or preventing a blood disorder in a subject, comprising administering to said subject an effective amount of a compound of formula I:
Figure US20080075692A1-20080327-C00085
wherein
R1 is hydroxy or alkoxy;
X is C(O), C(S), SO, SO2 or PO2;
R2 and R3 are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
R4 is alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, halogen or
Figure US20080075692A1-20080327-C00086
R5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R6 to form a ring;
R6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R5 or R7 to form a ring;
R7 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R6 or R8 to form a ring;
R8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R7 or R9 to form a ring;
R9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R8 to form a ring;
and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
provided that when R4 is
Figure US20080075692A1-20080327-C00087
 R5, R6, R7, R8, and R9 are each not hydrogen; and when R6, R7, R8, and R9 are each hydrogen, R5 is not methoxy; and when R5, R7, R8, R9 are hydrogen, R6 is not methoxy; and when R5, R8 and R9 are hydrogen, R6 and R7 are not methoxy.
2. The method of claim 1, wherein R1 is hydroxy, X is C(O), R4 is
Figure US20080075692A1-20080327-C00088
and R2, R3 and R5 are each hydrogen.
3. The method of claim 2, wherein R6, R8 and R9 are each hydrogen, and R7 is alkoxy.
4. The method of claim 3, wherein R7 is methoxy.
5. The method of claim 2, wherein R7 and R8 are each hydrogen, and R6 and R9 are each alkyl.
6. The method of claim 5, wherein R6 and R9 are methyl.
7. The method of claim 2, wherein R8 are R9 are each hydrogen and R6 and R7 are each hydroxyl.
8. The method of claim 2, wherein R8 are R9 are each hydrogen and R6 and R7 are linked by —O—CH2—O— to form a ring.
9. The method of claim 2, wherein R6 and R9 are each hydrogen, R7 is alkoxy and R8 is hydroxyl.
10. The method of claim 1, wherein R4 is heteroaryl.
11. The method of claim 10, wherein R4 is quinoline or substituted or unsubstituted thiophene.
12. The method of claim 11, wherein R4 is chlorothiophene.
13. The method of claim 1, wherein said compound is:
Figure US20080075692A1-20080327-C00089
14. A method for treating or preventing a blood disorder in a subject, comprising administering to said subject an effective amount of a compound of formula II:
Figure US20080075692A1-20080327-C00090
wherein
R1′ is hydroxy or alkoxy;
Y is C(O);
n is 0 or an integer from 1 to 5;
R10 and R10′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino, heterocyclic or optionally joined to form a ring;
R11 is CR11′R11″R11′″, alkenyl, cycloalkyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, carbonylalkyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxy, halogen or
Figure US20080075692A1-20080327-C00091
R11′ and R11″ are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxyl, halogen or R11′ and R11″ are optionally joined to form a ring;
R11′″ is alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or halogen;
R12 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic or optionally linked to R13 to form a ring;
R13 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or optionally linked to R12 or R14 to form a ring;
R14 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R13 or R15 to form a ring;
R15 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R14 or R16 to form a ring;
R16 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R15 to form a ring;
and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
provided that when R11 is
Figure US20080075692A1-20080327-C00092
 R12, R13, R14, R15, and R16 are each not hydrogen; and provided when n is 2, R11 is
Figure US20080075692A1-20080327-C00093
 and R10, R10′, R12, R15, and R16 are hydrogen, then R14 and R15 are not methoxy; and provided when n is 1, R11 is
Figure US20080075692A1-20080327-C00094
 and R10, R10′, R13, R14, and R16 are hydrogen, then R12 and R15 are not methoxy.
15. The method of claim 14, wherein R1′ is hydroxy.
16. The method of claim 15, wherein n is 5, R10 and R10′ are hydrogen and R11 is alkylcarbonyl.
17. The method of claim 15, wherein n is 2, R10 and R10′ are each hydrogen and R11 is CR11′R11″R11′″.
18. The method of claim 17, wherein R11′ and R11″ are joined by —(CH2)5— to form a cyclohexyl ring and R11′″ is a substituted or unsubstituted heterocycle.
19. The method of claim 18, wherein R11′″ is chlorothiophene.
20. The method of claim 15, wherein n is 0.
21. The method of claim 20, wherein R11 is
Figure US20080075692A1-20080327-C00095
22. The method of claim 21, wherein R13, R14, R15, and R16 are hydrogen.
23. The method of claim 22, wherein R12 is arylthioalkyl.
24. The method of claim 22, wherein R12 is alkoxy substituted aryloxy.
25. The method of claim 21, wherein R12, R14, R15 and R16 are hydrogen.
26. The method of claim 25, wherein R13 is a substituted or unsubstituted heterocycle.
27. The method of claim 26, wherein R13 is chromen-2-one, nitro-substituted pyrazole, or chloro-substituted pyrazole.
28. The method of claim 21, wherein R12, R13, R15 and R16 are hydrogen and R13 is alkoxy.
29. The method of claim 28, wherein R13 is ethoxy.
30. The method of claim 21, wherein R12, R15 and R16 are hydrogen, and R13 and R14 are linked by —N(H)C(O)CH2S— to form a ring.
31. The method of claim 21, wherein R14, R15 and R16 are each hydrogen, and R12 and R13 are linked by —CH═C(CH3)O— to form a ring.
32. The method of claim 20, wherein R11 is a substituted or unsubstituted heterocycle.
33. The method of claim 32, wherein R11 is a substituted aryl-substituted furan.
34. The method of claim 20, wherein R11 is a substituted or unsubstituted cycloalkyl.
35. The method of claim 34, wherein R11 is tetrahydrobenzothiadiazole or dihydrobenzothiophenone.
36. The method of claim 15, wherein n is 1.
37. The method of claim 36, wherein R10 and R10′ are hydrogen.
38. The method of claim 37, wherein R11 is a substituted or unsubstituted cycloalkyl.
39. The method of claim 38, wherein R11 is dimethylcyclobutane carboxylic acid.
40. The method of claim 37, wherein R11 is
Figure US20080075692A1-20080327-C00096
41. The method of claim 40, wherein R12, R13 and R16 are hydrogen, and R14 and R15 are linked by —O—CH2—O— to form a ring.
42. The method of claim 37, wherein R11 is a substituted or unsubstituted heterocycle.
43. The method of claim 42, wherein R11 is substituted thiazolidinedione, substituted pyridinone or substituted pyrazole.
44. The method of claim 37, wherein R11 is substituted or unsubstituted arylamino.
45. The method of claim 44, wherein R11 arylamino is trifluorothio-substituted arylamino.
46. The method of claim 37, wherein R11 is substituted or unsubstituted arylthio or substituted or unsubstituted heterocyclic thio.
47. The method of claim 46, wherein R11 is methoxyphenylthio.
48. The method of claim 46, said R11 is substituted triazolethio, substituted thiadiazolethio or substituted thiophenethio.
49. The method of claim 37, wherein R11 is CR11′R11″R11′″.
50. The method of claim 49, wherein R11′ is hydrogen, R11″ is amino and R11′″ is alkoxy-substituted aryl.
51. The method of claim 36, wherein R10 is hydrogen and R10′ is alkyl.
52. The method of claim 51, wherein R10′ is isopropyl.
53. The method of claim 52, wherein R11 is substituted or unsubstituted arylthio.
54. The method of claim 53, wherein R11 is alkoxy-substituted phenylthio or alkoxy-substituted pyrimadinylthio.
55. The method of claim 51, wherein R10′ is ethyl.
56. The method of claim 55, wherein R11 is heteroarylamino.
57. The method of claim 56, wherein R11 is quinazolinylamino.
58. The method of claim 36, wherein R10 and R10′ are linked by —(CH2)5— to form a cyclohexyl ring.
59. The method of claim 58, wherein R11 is heterocyclic substituted carbonylalkyl.
60. The method of claim 14, wherein said compound is
Figure US20080075692A1-20080327-C00097
Figure US20080075692A1-20080327-C00098
Figure US20080075692A1-20080327-C00099
61. A method for treating or preventing a blood disorder in a subject, comprising administering to said subject an effective amount of a compound of formula III:
Figure US20080075692A1-20080327-C00100
wherein
R1″ is hydroxy or alkoxy;
Z is C(S), SO, SO2 or PO2;
m is 0 or an integer from 1-5;
R17 and R17′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
R18 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxyl or halogen;
and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof.
62. The method of claim 61, wherein R1″ is hydroxyl, Z is SO2, m is 0, and R18 is disubstituted aryl.
63. The method of claim 62, wherein R18 is substituted by nitro and fluoro.
64. The method of claim 61, wherein the compound is of the formula:
Figure US20080075692A1-20080327-C00101
65. A method for treating or preventing a blood disorder in a subject, comprising administering to said subject an effective amount of a compound of formula:
Figure US20080075692A1-20080327-C00102
66. The method of any one of claims 1, 14, 61 or 65, wherein the blood disorder is sickle cell anemia, β-thalassemia, neutropenia or thrombocytopenia.
67. The method of any one of claims 1, 14, 61 or 65, wherein said compound stimulates fetal hemoglobin production.
68. The method of any one of claim 1, 14, 61 or 65, wherein said compound stimulates hematopoiesis.
69. The method of any one of claims 1, 14, 61 or 65, wherein said compound stimulates erythropoiesis.
70. The method of any one of claims 1, 14, 61 or 65, wherein said compound stimulates myelopoiesis.
71. The method of any one of claims 1, 14, 61 or 65, wherein said compound stimulates neutrophil production.
72. The method of any one of claims 1, 14, 61 or 65, wherein said compound is administered in combination with one or more cytokines.
73. The method of claim 72, wherein said cytokine is selected from the group consisting of IL-3, GM-CSF, C-CSF, SCF and IL-6.
74. A pharmaceutical composition comprising an effective amount of a compound of any one of claims 1, 13, 14, 60, 61 or 65 and racemates, isolated enantiomers or diastereomers thereof, and a pharmaceutically acceptable carrier.
75. A compound of formula I:
Figure US20080075692A1-20080327-C00103
wherein
R1 is hydroxy or alkoxy;
X is C(O), C(S), SO, SO2 or PO2;
R2 and R3 are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
R4 is alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, halogen or
Figure US20080075692A1-20080327-C00104
R5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R6 to form a ring;
R6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R5 or R7 to form a ring;
R7 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R6 or R8 to form a ring;
R8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R7 or R9 to form a ring;
R9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R8 to form a ring;
and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
provided that when R4 is
Figure US20080075692A1-20080327-C00105
 R5, R6, R7, R8, and R9 are each not hydrogen; and when R6, R7, R8, and R9 are each hydrogen, R5 is not methoxy; and when R5, R7, R8, R9 are hydrogen, R6 is not methoxy; and when R5, R8 and R9 are hydrogen, R6 and R7 are not methoxy;
and provided that the compound is not a compound of claim 13.
76. A compound of formula II:
Figure US20080075692A1-20080327-C00106
wherein
R1′ is hydroxy or alkoxy;
Y is C(O);
n is 0 or an integer from 1 to 5;
R10 and R10′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino, heterocyclic or optionally joined to form a ring;
R11 is CR11′R11″R11′″, alkenyl, cycloalkyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, carbonylalkyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxy, halogen or
Figure US20080075692A1-20080327-C00107
R11′ and R11″ are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxyl, halogen or R11′ and R11″ are optionally joined to form a ring;
R11′″ is alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or halogen;
R12 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic or optionally linked to R13 to form a ring;
R13 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy or optionally linked to R12 or R14 to form a ring;
R14 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R13 or R15 to form a ring;
R15 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R14 or R16 to form a ring;
R16 is hydrogen, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, halogen or optionally linked to R15 to form a ring;
and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
provided that when R11 is
Figure US20080075692A1-20080327-C00108
 R12, R13, R14, R15, and R16 are each not hydrogen; and provided when n is 2, R11 is
Figure US20080075692A1-20080327-C00109
 and R10, R10′, R12, R15, and R16 are hydrogen, then R14 and R15 are not methoxy; and provided when n is 1, R11 is
Figure US20080075692A1-20080327-C00110
and R10, R10′, R13, R14, and R16 are hydrogen, then R12 and R15 are not methoxy;
and provided that the compound is not a compound of claim 60.
77. A compound of formula III:
Figure US20080075692A1-20080327-C00111
wherein
R1″ is hydroxy or alkoxy;
Z is C(S), SO, SO2 or PO2;
m is 0 or an integer from 1-5;
R17 and R17′ are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic;
R18 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, hydroxyl or halogen;
and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof;
provided that the compound is not a compound of claim 64.
US11/746,543 2006-05-09 2007-05-09 Methods for treating blood disorders Abandoned US20080075692A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/746,543 US20080075692A1 (en) 2006-05-09 2007-05-09 Methods for treating blood disorders
US12/212,000 US8759378B2 (en) 2006-05-09 2008-09-17 Methods for treating blood disorders
US14/310,955 US9095565B2 (en) 2006-05-09 2014-06-20 Methods for treating blood disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79905406P 2006-05-09 2006-05-09
US11/746,543 US20080075692A1 (en) 2006-05-09 2007-05-09 Methods for treating blood disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/212,000 Continuation US8759378B2 (en) 2006-05-09 2008-09-17 Methods for treating blood disorders

Publications (1)

Publication Number Publication Date
US20080075692A1 true US20080075692A1 (en) 2008-03-27

Family

ID=38626483

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/746,543 Abandoned US20080075692A1 (en) 2006-05-09 2007-05-09 Methods for treating blood disorders
US12/212,000 Active 2029-09-12 US8759378B2 (en) 2006-05-09 2008-09-17 Methods for treating blood disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/212,000 Active 2029-09-12 US8759378B2 (en) 2006-05-09 2008-09-17 Methods for treating blood disorders

Country Status (9)

Country Link
US (2) US20080075692A1 (en)
EP (1) EP2023913A2 (en)
JP (1) JP2009536659A (en)
CN (1) CN101489544A (en)
AU (1) AU2007249827A1 (en)
BR (1) BRPI0713096A2 (en)
CA (1) CA2652235A1 (en)
EA (1) EA200802213A1 (en)
WO (1) WO2007133653A2 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090005308A1 (en) * 2007-02-02 2009-01-01 Acceleron Pharma Inc. Variants derived from ACTRIIB and uses therefor
US20090047281A1 (en) * 2006-12-18 2009-02-19 Sherman Matthew L Activin-ActRII antagonists and uses for increasing red blood cell levels
US20090074768A1 (en) * 2007-02-01 2009-03-19 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
US20090098113A1 (en) * 2005-11-23 2009-04-16 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for promoting bone growth
US20090118188A1 (en) * 2007-09-18 2009-05-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting FSH secretion
US20090142333A1 (en) * 2007-02-09 2009-06-04 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
US20090311252A1 (en) * 2005-11-23 2009-12-17 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
US20100008918A1 (en) * 2008-06-26 2010-01-14 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US20100028331A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100068215A1 (en) * 2008-08-14 2010-03-18 Acceleron Pharma Inc. Use of GDF traps to increase red blood cell levels
WO2009158033A3 (en) * 2008-06-26 2010-04-01 Acceleron Pharma Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100183624A1 (en) * 2009-01-13 2010-07-22 Jasbir Seehra Methods for increasing adiponectin
US20100267133A1 (en) * 2004-07-23 2010-10-21 Acceleron Pharma Inc. Acrtiib-fc polynucleotides, polypeptides, and compositions
US20100310577A1 (en) * 2009-06-08 2010-12-09 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US20110038831A1 (en) * 2008-08-14 2011-02-17 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
US20110070233A1 (en) * 2009-09-09 2011-03-24 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
US20110129469A1 (en) * 2009-11-03 2011-06-02 Acceleron Pharma Inc. Methods for treating fatty liver disease
US20110135638A1 (en) * 2009-11-17 2011-06-09 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US20110177033A1 (en) * 2010-01-20 2011-07-21 Academia Sinica Ras responsive element binding protein 1 (rreb1) as a therapeutic target for thalassemias and sickle cell anemia
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
US9493556B2 (en) 2010-11-08 2016-11-15 Acceleron Pharma Inc. Actriia binding agents and uses thereof
US9850298B2 (en) 2014-06-13 2017-12-26 Acceleron Pharma Inc. Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
WO2019084402A1 (en) * 2017-10-27 2019-05-02 St. Jude Children's Research Hospital Method for treating thalassemia
US11471510B2 (en) 2014-12-03 2022-10-18 Celgene Corporation Activin-ActRII antagonists and uses for treating anemia
US11813308B2 (en) 2014-10-09 2023-11-14 Celgene Corporation Treatment of cardiovascular disease using ActRII ligand traps

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040883A2 (en) 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
US8741966B2 (en) 2007-11-09 2014-06-03 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
ES2875944T3 (en) 2008-03-18 2021-11-11 Arena Pharm Inc Prostacyclin (PG12) receptor modulators useful for treating prostacyclin-related disorders
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
EP3342767B1 (en) 2008-11-26 2021-04-14 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
EP2370413B1 (en) 2008-12-08 2015-08-05 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
MX366137B (en) 2009-05-08 2019-06-28 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas.
CN101653449B (en) * 2009-09-11 2012-05-23 南京大学 Application of ADDA and/or DMTA in preparing medicine for improving expression level of gamma-globin
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
EP2509418A4 (en) * 2009-12-08 2013-03-20 Hemaquest Pharmaceuticals Inc Methods and low dose regimens for treating red blood cell disorders
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
MX350720B (en) 2010-11-05 2017-09-14 Pronova Biopharma Norge As Methods of treatment using lipid compounds.
US9018176B2 (en) 2010-12-02 2015-04-28 Susan Perrine Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
EP2961384B1 (en) 2013-02-28 2019-08-28 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2014191726A1 (en) 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
CA3120111A1 (en) * 2013-08-20 2015-02-26 Phoenicia Biosciences, Inc. Chemical inducers of fetal hemoglobin
EA201790905A1 (en) 2014-10-23 2017-09-29 Арена Фармасьютикалз, Инк. METHOD FOR TREATING STATES CONNECTED WITH PGI2 RECEPTOR
JP6784696B2 (en) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス Use of structurally fortified fatty acids containing sulfur for the prevention and / or treatment of non-alcoholic steatohepatitis
AU2018227842B2 (en) 2017-03-01 2024-05-02 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
MA50250A (en) 2017-09-15 2020-07-22 Forma Therapeutics Inc TETRAHYDROIMIDAZO QUINOLEIN COMPOSITIONS USED AS CBP / P300 INHIBITORS
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
SG11202012767UA (en) 2018-06-29 2021-01-28 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
CN112812006A (en) * 2020-12-30 2021-05-18 广州城市职业学院 P-hydroxyacetophenone hapten, artificial antigen, and synthesis method and application thereof
MX2024004801A (en) 2021-10-19 2024-06-28 Akirabio Inc Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers.
IL314717A (en) 2022-02-15 2024-10-01 United Therapeutics Corp Crystalline prostacyclin (ip) receptor agonist and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704402A (en) * 1982-06-12 1987-11-03 University Of Pittsburgh Method of treating sickle cell anemia
US4968340A (en) * 1988-06-20 1990-11-06 Kumiai Chemical Industry Co., Ltd. Alkanoic acid derivatives and herbicidal compositions
US5139563A (en) * 1989-06-02 1992-08-18 Shell Research Limited Herbicidal compounds
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025029A (en) * 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
EP0371789B1 (en) * 1988-11-29 1997-01-02 Children's Hospital Medical Center Of Northern California Medicament for augmenting fetal hemoglobin
US5569675A (en) * 1994-03-07 1996-10-29 Bar Ilan University Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704402A (en) * 1982-06-12 1987-11-03 University Of Pittsburgh Method of treating sickle cell anemia
US4968340A (en) * 1988-06-20 1990-11-06 Kumiai Chemical Industry Co., Ltd. Alkanoic acid derivatives and herbicidal compositions
US5139563A (en) * 1989-06-02 1992-08-18 Shell Research Limited Herbicidal compounds
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138459B2 (en) 2004-07-23 2015-09-22 Acceleron Pharma Inc. ACTRIIB-FC polynucleotides, polypeptides, and compositions
US20100267133A1 (en) * 2004-07-23 2010-10-21 Acceleron Pharma Inc. Acrtiib-fc polynucleotides, polypeptides, and compositions
US8252900B2 (en) 2004-07-23 2012-08-28 Acceleron Pharma Inc. Actriib-Fc polynucleotides, polypeptides, and compositions
US10239940B2 (en) 2005-11-23 2019-03-26 Acceleron Pharma Inc. Method of promoting bone growth by an anti-actriia antibody
US10071135B2 (en) 2005-11-23 2018-09-11 Acceleron Pharma Inc. Method of identifying an agent that promotes bone growth or increases bone density
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7951771B2 (en) 2005-11-23 2011-05-31 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for promoting bone growth
US20090311252A1 (en) * 2005-11-23 2009-12-17 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
US20090098113A1 (en) * 2005-11-23 2009-04-16 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for promoting bone growth
US9572865B2 (en) 2005-11-23 2017-02-21 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating multiple myeloma
US11129873B2 (en) 2005-11-23 2021-09-28 Acceleron Pharma Inc. Method for promoting bone growth using activin-actriia antagonists
US8486403B2 (en) 2005-11-23 2013-07-16 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin A antibody
US8629109B2 (en) 2005-11-23 2014-01-14 Acceleron Pharma Inc. Method for promoting bone growth using activin-actriia antagonists
US9480742B2 (en) 2005-11-23 2016-11-01 Acceleron Pharma Inc. Method of promoting bone growth by an anti-actriia antibody
US9163075B2 (en) 2005-11-23 2015-10-20 Acceleron Pharma Inc. Isolated polynucleotide that encodes an ActRIIa-Fc fusion polypeptide
US8067360B2 (en) 2005-11-23 2011-11-29 Acceleron Pharma Inc. Method for promoting bone growth using activin-ActRIIa antagonists
US20090163417A1 (en) * 2006-12-18 2009-06-25 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028331A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US7988973B2 (en) 2006-12-18 2011-08-02 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for increasing red blood cell levels
US10093707B2 (en) 2006-12-18 2018-10-09 Acceleron Pharma Inc. Antagonists of activin-ActRIIa and uses for increasing red blood cell levels
US20090047281A1 (en) * 2006-12-18 2009-02-19 Sherman Matthew L Activin-ActRII antagonists and uses for increasing red blood cell levels
US8007809B2 (en) 2006-12-18 2011-08-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US9526759B2 (en) 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
US20090074768A1 (en) * 2007-02-01 2009-03-19 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
US7842663B2 (en) 2007-02-02 2010-11-30 Acceleron Pharma Inc. Variants derived from ActRIIB and uses therefor
US20090005308A1 (en) * 2007-02-02 2009-01-01 Acceleron Pharma Inc. Variants derived from ACTRIIB and uses therefor
US9399669B2 (en) 2007-02-02 2016-07-26 Acceleron Pharma Inc. Variants derived from ActRIIB
US8343933B2 (en) 2007-02-02 2013-01-01 Acceleron Pharma, Inc. Variants derived from ActRIIB and uses therefor
US20110092670A1 (en) * 2007-02-02 2011-04-21 Acceleron Pharma Inc. Variants derived from actriib and uses therefor
US10259861B2 (en) 2007-02-02 2019-04-16 Acceleron Pharma Inc. Variants derived from ActRIIB and uses therefor
US8173601B2 (en) 2007-02-09 2012-05-08 Acceleron Pharma, Inc. Activin-ActRIIa antagonists and uses for treating multiple myeloma
US20090142333A1 (en) * 2007-02-09 2009-06-04 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
US20090118188A1 (en) * 2007-09-18 2009-05-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting FSH secretion
US20110218147A1 (en) * 2007-09-18 2011-09-08 Acceleron Pharma Inc. Activin-actriia antagonists for inhibiting germ cell maturation
US8367611B2 (en) 2007-09-18 2013-02-05 Acceleron Pharma Inc. Activin-actriia antagonists for inhibiting germ cell maturation
US9353356B2 (en) 2007-09-18 2016-05-31 Acceleron Pharma Inc. Activin-actriia antagonists for treating a follicle-stimulating horomone-secreting pituitary tumor
US20100008918A1 (en) * 2008-06-26 2010-01-14 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
US20100015144A1 (en) * 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
WO2009158033A3 (en) * 2008-06-26 2010-04-01 Acceleron Pharma Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US11162085B2 (en) 2008-08-14 2021-11-02 Acceleron Pharma Inc. Methods for treating anemia in a subject in need thereof
US20110038831A1 (en) * 2008-08-14 2011-02-17 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
US10689427B2 (en) 2008-08-14 2020-06-23 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
US8058229B2 (en) 2008-08-14 2011-11-15 Acceleron Pharma Inc. Method of increasing red blood cell levels or treating anemia in a patient
US11168311B2 (en) 2008-08-14 2021-11-09 Acceleron Pharma Inc. Methods for treating anemia in a subject in need thereof
US9932379B2 (en) 2008-08-14 2018-04-03 Acceleron Pharma Inc. Isolated nucleotide sequences encoding GDF traps
US11155791B2 (en) 2008-08-14 2021-10-26 Acceleron Pharma Inc. Methods for treating anemia in a subject in need thereof
US10377996B2 (en) 2008-08-14 2019-08-13 Acceleron Pharma Inc. Methods of identifying ActRIIB variants
US8703927B2 (en) 2008-08-14 2014-04-22 Acceleron Pharma Inc. Isolated nucleotide sequences encoding GDF traps
US8361957B2 (en) 2008-08-14 2013-01-29 Acceleron Pharma, Inc. Isolated GDF trap polypeptide
US9439945B2 (en) 2008-08-14 2016-09-13 Acceleron Pharma Inc. Isolated nucleotide sequences encoding GDF traps
US10829532B2 (en) 2008-08-14 2020-11-10 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
US10889626B2 (en) 2008-08-14 2021-01-12 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
US9505813B2 (en) 2008-08-14 2016-11-29 Acceleron Pharma Inc. Use of GDF traps to treat anemia
US20100068215A1 (en) * 2008-08-14 2010-03-18 Acceleron Pharma Inc. Use of GDF traps to increase red blood cell levels
US10829533B2 (en) 2008-08-14 2020-11-10 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
US20100183624A1 (en) * 2009-01-13 2010-07-22 Jasbir Seehra Methods for increasing adiponectin
US8765663B2 (en) 2009-01-13 2014-07-01 Acceleron Pharma Inc. Methods for increasing adiponectin
US8703694B2 (en) 2009-06-08 2014-04-22 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
US9790284B2 (en) 2009-06-08 2017-10-17 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US20100310577A1 (en) * 2009-06-08 2010-12-09 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US10968282B2 (en) 2009-06-08 2021-04-06 Acceleron Pharma Inc. Methods for screening compounds for increasing thermogenic adipocytes
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
US9745559B2 (en) 2009-06-12 2017-08-29 Acceleron Pharma Inc. Method for decreasing the body fat content in a subject by administering an ActRIIB protein
US11066654B2 (en) 2009-06-12 2021-07-20 Acceleron Pharma Inc. Methods and compositions for reducing serum lipids
US10358633B2 (en) 2009-06-12 2019-07-23 Acceleron Pharma Inc. Method for producing an ActRIIB-Fc fusion polypeptide
US9181533B2 (en) 2009-06-12 2015-11-10 Acceleron Pharma, Inc. Truncated ACTRIIB-FC fusion protein
US20110070233A1 (en) * 2009-09-09 2011-03-24 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
US20110129469A1 (en) * 2009-11-03 2011-06-02 Acceleron Pharma Inc. Methods for treating fatty liver disease
US20110135638A1 (en) * 2009-11-17 2011-06-09 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9617319B2 (en) 2009-11-17 2017-04-11 Acceleron Pharma Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US10968262B2 (en) 2009-11-17 2021-04-06 Acceleron Pharma Inc. Methods of increasing sarcolemmal utrophin
US20110177033A1 (en) * 2010-01-20 2011-07-21 Academia Sinica Ras responsive element binding protein 1 (rreb1) as a therapeutic target for thalassemias and sickle cell anemia
US9493556B2 (en) 2010-11-08 2016-11-15 Acceleron Pharma Inc. Actriia binding agents and uses thereof
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
US9850298B2 (en) 2014-06-13 2017-12-26 Acceleron Pharma Inc. Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide
US10487144B2 (en) 2014-06-13 2019-11-26 Acceleron Pharma Inc. Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptide
US11260107B2 (en) 2014-06-13 2022-03-01 Acceleron Pharma Inc. Methods and compositions for treating ulcers
US11813308B2 (en) 2014-10-09 2023-11-14 Celgene Corporation Treatment of cardiovascular disease using ActRII ligand traps
US11471510B2 (en) 2014-12-03 2022-10-18 Celgene Corporation Activin-ActRII antagonists and uses for treating anemia
WO2019084402A1 (en) * 2017-10-27 2019-05-02 St. Jude Children's Research Hospital Method for treating thalassemia
US11298343B2 (en) 2017-10-27 2022-04-12 St. Jude Children's Research Hospital Method for treating thalassemia

Also Published As

Publication number Publication date
BRPI0713096A2 (en) 2012-10-16
CN101489544A (en) 2009-07-22
EP2023913A2 (en) 2009-02-18
EA200802213A1 (en) 2009-10-30
AU2007249827A1 (en) 2007-11-22
WO2007133653A3 (en) 2008-01-24
WO2007133653A2 (en) 2007-11-22
US20090137567A1 (en) 2009-05-28
JP2009536659A (en) 2009-10-15
US8759378B2 (en) 2014-06-24
CA2652235A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
US8759378B2 (en) Methods for treating blood disorders
US5569675A (en) Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
CN1993119B (en) Composition containing statins and omega-3 fatty acids
JP2017014293A (en) Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US20030144350A1 (en) Fat accumulation-modulation compounds
Songsiridej et al. Methotrexate—the rapidly acting drug
CN106146337A (en) For treating the naphtoquinone compounds of the disease of APE1 mediation
US9095565B2 (en) Methods for treating blood disorders
CN1275594C (en) Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
US11873299B1 (en) 7-(4-((5-(4-chlorobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)iperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory compound
JP2011530525A (en) Novel methylenedioxyphenolic compounds and their use for disease treatment
AU629533B2 (en) Improving toxicity profiles in chemotherapy
EP1889613A1 (en) Pharmaceutical composition comprising vitamin k
JP2014521738A (en) Koror and statin combination
US8513430B2 (en) Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
JP2022517130A (en) Methods for treating substituted condensed imidazole derivatives and sickle cell disease and related complications
AU657825B2 (en) Substituted benzaldehyde derivatives
US20210163308A1 (en) Compositions and methods for the modulation of cytokines
AU687975B2 (en) Pharmaceutical compositions
US11884659B1 (en) 1-cyclopropyl-6-fluoro-4-oxo-7-(4-((5-(quinolin-2-ylmethyleneamino)-2-thioxo-1,3,4- thiadiazol-3(2H)-yl)methyl) piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory compound
AU2016277929B2 (en) Combination therapy using belinostat and pralatrexate to treat lymphoma
US11919893B1 (en) 7-(4-((5-(2-bromobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl) piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory compound
US11891385B1 (en) 1-cyclopropyl-7-(4-((5-(3,5-dichlorobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic aci d as an anti-inflammatory compound
US11926601B1 (en) 5-spiro 9,10-dihydroanthracene derivative of imidazolidine-2,4-dione as an anticancer agent
US11905261B1 (en) 3-(4-methoxyphenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole as an antitumor and antimicrobial compound

Legal Events

Date Code Title Description
AS Assignment

Owner name: HEMAQUEST PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PERRINE, SUSAN P.;REEL/FRAME:020173/0573

Effective date: 20071126

AS Assignment

Owner name: HEMAQUEST PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:HEMAGENEX PHARMACEUTICALS, INC.;REEL/FRAME:020192/0871

Effective date: 20071107

AS Assignment

Owner name: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, COL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WILLIAMS, ROBERT M;GRESHOCK, THOMAS J;REEL/FRAME:021788/0731;SIGNING DATES FROM 20081013 TO 20081030

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION